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ABSTRACT 
 
Coronary heart disease (CHD) remains the leading cause of death throughout the 
world, and postmenopausal women are at particularly high risk for CHD. A promising 
new avenue of study is the novel G protein-coupled estrogen receptor (GPER) which 
mediates estrogen action. The major purpose of my studies in this dissertation is to 
investigate the role of GPER in porcine coronary artery tone regulation. In a series of 
studies, we tested four hypotheses: 1) activation of GPER regulates coronary artery tone 
by paradoxically inducing relaxation and potentiating contraction; 2) activation of GPER 
induces coronary artery relaxation by Gs/cAMP-dependent pathway(s); 3) activation of 
GPER induces coronary artery relaxation via inhibition of RhoA/Rho kinase pathway by 
cAMP downstream targets: the exchange proteins directly activated by cAMP (Epac) as 
well as PKA; and 4) activation of GPER potentiates coronary artery contraction by a 
Gβγ/EGFR-dependent pathway. Isometric tension studies were performed on 
endothelium-denuded porcine coronary arteries to test the function role of GPER and its 
signaling pathways. RT-PCR, Western blots, patch-clamp experiments and kinase 
activity assays also were employed in these studies to confirm the expression and 
phosphorylation of subjective proteins, channel activities and kinase activities in porcine 
and human coronary artery smooth muscle cells (SMCs) and coronary artery tissues. 
Results from these studies suggest: 1) GPER is expressed in porcine and human 
coronary artery SMCs; 2) GPER mediated coronary artery relaxation is NO-independent 
and involves BKCa channel activity; 3) activation of GPER stimulates the production of 
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cAMP, thus activates its downstream targets PKA and Epac; 4) GPER mediates 
coronary relaxation through activation of MLCP via inhibition of RhoA activity by both 
PKA and Epac; 5) the interaction between AKAP and PKA is involved in the 
cAMP/PKA signaling mediated by GPER in coronary artery; and 6) GPER potentiates 
coronary artery contraction via Gβγ signaling to stimulate transactivation of  EGFR and 
activation of ERK1/2. These findings provided evidence of the dual effects of GPER in 
coronary regulation, which may help reveal the controversial actions of estrogen and 
provide a molecular basis for developing new compounds that better target estrogen 
signaling for a variety of clinical applications. 
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CHAPTER I 
INTRODUCTION 
 
1.1 INTRODUCTION 
"While I was going through menopause, I was also going through a divorce,” 
said my Aunt Jane. Her overwhelming physical and emotional problems caused her to 
lose interest in her family and her job, leading even to an attempted suicide. After her 
children forced her to see a doctor, Jane was diagnosed as having severe menopausal 
depression and was immediately placed on hormone replacement therapy. As a result of 
her supplemental female sex hormones, Jane no longer suffers from menopausal 
symptoms and her quality of life has been restored; however, unfortunately, her marriage 
could not recover. 
My Aunt Jane is not alone! According to statistics generated from the Women’s 
Health Initiative trial, all women ages 45 to 55 in the U.S. are suffering from a variety of 
menopausal symptoms, to some extent. As estrogen levels decline in menopause there is 
an increase in long-term serious health risks – most notably an increased incidence of 
coronary artery disease. The findings of my studies will help better understand and 
harness the therapeutic potential of estrogen and provide the many health benefits of 
estrogen while limiting the potentially dangerous side effects, therefore improving the 
quality of life for thousands of women. 
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1.2 ESTROGEN 
1.2.1 Estrogens and classical receptors 
There are three major naturally occurring estrogens in females: estrone (E1), 
estradiol (E2) and estriol (E3). E2 is mainly produced in the ovaries and is most potent 
and predominant. Estrogenically weak estrone (E1) and estriol (E3) must be converted to 
estradiol (E2) to show full estrogenic actions. Estrogens circulate in the bloodstream and 
bind to their receptors, affecting not only uterus and female breasts, but also heart, brain, 
bone, liver and other targeted tissues. Classically, there are two different forms of 
estrogen receptors (ER): ERα and ERβ which are encoded by ESR1 (70) and ESR2 (150) 
respectively in human. Both estrogen receptors are widely expressed in many tissues.  
The effects of estrogens are mediated by either non-genomic/rapid mechanism 
which happens within minutes of cell stimulations, or genomic mechanism that occurs in 
hours (83, 138) (Fig. 1). Lipophilic estrogens freely pass through lipid bilayer membrane 
of cells and bind to estrogen receptors. The ligand-receptor complex goes through 
nuclear membrane, specifically binds to estrogen response element (ERE), a specific 
DNA sequence, and promotes the gene transcription. Additionally, plasma membrane 
localized estrogen receptors elicit the rapid response by activating 2nd messengers, 
stimulating downstreamphosphatidylinositol-3(PI3K)/Akt, protein kinase C (PKC) 
and/or mitogen activated protein kinase (MAPK) and initiating physiological effects. 
Even in the absence of ligands, nuclear receptors also can be stimulated by growth factor 
such as  epidermal growth factor (EGF)  and mediate genomic effects (83). 
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Figure 1. Genomic and non-genomic mechanisms of estrogen. A. genomic mechanism. 
B. non-genomic mechanism. C. ligands-independent pathway. ERs: estrogen receptors. 
ERE: estrogen response element. GF: growth factor. EGFR: epidermal growth factor 
receptor. Adapted from Ref. 153. 
 
1.2.2 Estrogen actions on reproductive system 
Estrogens present in female bodies in significantly high amounts from puberty 
until menopause and the primary function of estrogens is to promote development and 
maintenance of female secondary sex characteristics and reproduction. Generally, 
estrogens promote formation of the female reproductive tract, development of genitalia 
and breasts, distribution of female fat, growth of follicle, uterus preparation for 
implantation and  stimulation of myometrial excitability (229). In breast tissue, for 
example, estrogens induce the proliferation of mammary gland cells and prepare the 
breasts ready for milk production during pregnancy. Estrogens also stimulate the 
proliferation of the endometrium of the uterus and prepare the uterus for implantation of 
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an embryo. After an embryo is implanted, estrogens work in coordination with 
progestins and other fetal hormones to control the differentiation of the fetus.  
 
1.2.3 Estrogen actions on vascular system 
Estrogens bind to their receptors on vascular endothelial cells, vascular smooth 
muscle cells and myocardial cells (71), eliciting physiological effects. Estrogens alter the 
progress of vascular diseases by influencing vasoactive molecules, proliferation of 
endothelium and smooth muscle cells, serum lipids and coagulation factors.  
 
Estrogen influence on endothelial function 
Endothelium, previously thought as only a single thin layer of cells lining the 
interior wall of blood vessels, is now proven to be involved in many aspects of vascular 
biology. Endothelium regulates vascular tone by producing and releasing various 
endothelium-derived vasoactive factors. Estrogens activate nitric oxide synthase and 
prostacyclin synthase subsequently increasing the production of nitric oxide and 
prostacyclin, which induce vasodilation immediately after estrogens are administered. 
Long-term administration of estrogens increase expression of  genes for both 
vasodilatory enzymes nitric oxide synthase and prostacyclin synthase (18), and decrease 
the plasma concentrations of vasoconstrictors renin and endothelin-1 (26). Estrogens 
also accelerate the proliferation of endothelial cells, inhibit apoptosis of endothelial cells 
(206) and inhibit the growth of smooth muscle cells, thereby, contributing to vascular 
protection against vascular injury and atherosclerosis.  
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Estrogen influence on the serum lipids 
It is well accepted that the development of atherosclerosis is directly related to 
the elevated level of the oxidation of low-density lipoprotein (LDL). Oxidized LDL 
functions as an atherogenic factor through impairing endothelium-dependent relaxation 
and a chemotactic factor which stimulates circulating monocytes toward the lesion site 
of a vessel (35). In addition, macrophages uptake oxidized LDL and accumulate foam 
cells in the intima, which is the first step in the development of atherosclersosis. 
Oppositely, HDL inhibit and protect against LDL oxidation, reversing the formation of 
atherosclerosis lesion (16). The actions of estrogens on serum lipids are to reduce serum 
low-density lipoprotein (LDL) cholesterol concentration and to increase serum high-
density lipoprotein (HDL) cholesterol concentration (1), which further provides anti-
atherosclerotic effects.   
 
Estrogen influence on the coagulation system 
Blood coagulation consists of both pro-coagulation and anti-coagulation 
processes. Injury of vascular endothelium results in exposure of thrombocytes and 
activation of coagulation. The anti-coagulation system prevents over-coagulation, a 
pathological state of thrombosis (thrombophilia). In contrast to males, females show a 
higher estrogen-related physiological thrombophilia. Estrogens regulate coagulation by 
decreasing anticoagulant proteins and antifibrinolytic proteins, and increasing platelet 
adhesiveness (196), which is beneficial fora fetal implantation and a better placental 
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function during pregnancy (229). Therefore, pregnant women and women on oral 
contraceptives have higher risk of hypercoagulability.  
 
1.2.4 Estrogen actions on other systems 
Estrogen receptors are widely expressed in almost all body tissues and systems, 
such as bones, brain and immune system, and thus mediate critical widespread non-
reproductive effects. The major physiological effects of estrogen on bone are to reduce 
bone resorption and increase bone formation. Estrogens suppress the synthesis of bone-
resorbing cytokines (108), such as interleukin-1, interleukin-6 and tumor necrosis 
factors, and directly induce apoptosis of osteoclast cells (94). On the other side, 
estrogens inhibit apoptosis of osteoblast cells and increase proliferation and 
differentiation of the osteoblast directly (112). In brain, estrogens promote neuronal 
growth by protecting neurons from oxidative stress and ischemic injury and stimulating 
production of nerve growth factors (139). Some other estrogen effects on brain include 
regulating affective state and mood, modulating motor coordination, decreasing seizure 
threshold and influencing pain pathway (139). In the urinary system, estrogens prevent 
recurrent urinary tract infection in both young and postmenopausal women by improving 
urothelial defense mechanisms (132). Lastly, in the immune system, estrogens promote a 
more robust immune response by stimulating T cells and antigen-presenting cells (101). 
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1.3 MENOPAUSE 
1.3.1 Hormonal and pathophysiological changes during menopause 
Menopause is the end of menstruation and fertility, described as the permanent 
cessation of the primary functions of the ovaries, that is the growth of ovarian follicles 
and release of female sex hormones: estrogen and progesterone. Three types of 
circulating estrogens, which are mostly produced by the ovary prior to menopause, will 
decrease by 60% with major decrease in estradiol (E2) after menopause (25). The 
average age of menopause in U.S. is 51.3 years old according to the Massachusetts 
Women's Health Study (5) and the typical age range is between 40 and 61 years old 
(147). Although the average age for menopause in America is 51, menopausal symptoms 
can manifest even while a woman is in her forties. If one lives 80 years, then at least 
one-third or even one-half of a woman’s life will be “postmenopausal”. During this 
extended life period she will likely suffer from debilitating physical, mental, and 
emotional  symptoms, including headache, hot flashes, joint and muscle pains, sexual 
and urinary dysfunction, sleeplessness, and substantial “mood swings” affecting her and 
those around her. 
The perimenopausal period refers to the 2  to 8 years before and 1 year following 
the final menstrual period defined by World Health Organization (WHO) (228). During 
menopausal transition, the female body responses to the dramatic dropping of estrogens, 
and thus appears their regular menstrual cycles as well as many menopausal symptoms. 
Emotional symptoms includes headache, hot flashes, pains, sexual and urinary 
dysfunction, sleeplessness, and substantial “mood swings”; other changes includes brittle 
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nails, hair loss and joint and muscle pains. However, the even more devastating fact is 
that decreased estrogens increase the risk and incidence of vascular disease, 
dyslipidemia, and osteoporosis. Low circulating estrogens and low affinity to their 
receptors increase total cholesterol and triglyceride (136), alter coagulation factors to a 
more thrombogenic state (140), promote vasoconstriction, decrease endothelium 
functions, and enhance bone resorption (113). Briefly, there is no doubt that menopausal 
women are more susceptible to these diseases with age.  
 
 
 
 
Figure 2. Pathophysiology of menopause changes in cardiovascular system, bones and 
central nervous system.  CNS: central nervous system. NO: nitric oxide. Ang II: 
angiotensin II. HDL: high density lipoprotein. LDL: low density lipoprotein. NE: 
norepinephrine. Adapted from Ref. 229. 
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1.3.2 Prevalence of cardiovascular disease in postmenopausal females 
The deadliest consequence of menopause is cardiovascular disease. 
Premenopausal women aged from 20 to 39 years old have lower incidence of 
cardiovascular diseases, compared to the same age group of men; the gender difference 
dramatically decreases with the increase of age and becomes no different during the 
perimenopausal period (40-59 years old); while postmenopausal females > 60 years old 
even have higher incidence compared to the same aged males (Fig. 3). Women also 
show an significant increase in the incidence of coronary heart disease after bilateral 
oophorectomy (191). Nearly one in three postmenopausal women will die due to 
complications of cardiovascular diseases, in comparison, however, deaths due to breast 
cancer comprise only 2.8% (2). Most of cardiovascular diseases is coronary heart 
disease, also known as atherosclerotic heart disease or coronary artery disease.  
Coronary arteries run on the surface of the heart and deliver nutrient and oxygen-
rich blood to the distal myocardium. The two major coronary arteries that branch off 
from the root of the aorta are the left main coronary artery and right coronary artery, 
after which the left main artery branches into left anterior descending artery (LAD) and 
circumflex artery. Coronary artery disease is caused by buildup of plaque along the inner 
walls of coronary arteries, which narrows down the lumen of arteries and reduces blood 
flow to the distal myocardium. The left anterior descending artery is involved in 45% of 
atheroma; the right coronary artery is involved in 35%; and the left circumflex coronary 
artery is involved in 15% (22). Additional to the loss of estrogens' inhibition of the 
atherosclerosis process, deficiency of estrogen also puts females into high coagulant 
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states, thus making them at high risk of thrombogenesis, which worsens the condition of 
atherosclerosis.  
 
 
 
Figure 3. Percentage of population affected by cardiovascular disease between males 
and females with increasing age. The data is from National Health and Nutrition 
Examination Survey (NHANES) from 1999 to 2004, including coronary heart disease, 
heart failure, stroke and hypertension. 
 
1.3.3 Menopausal hormone replacement therapy 
Hormone replacement therapy (HRT) has been prescribed as a medication of 
menopause by physicians over 4 decades. A national survey (103) of postmenopausal 
women conducted in 1995 in U.S., aged from 50 to 75 years old, reports that 37.6% of 
women were taking HRT at the survey time. Obviously, HRT has been believed to be 
beneficial for postmenopausal women.  
Undoubtedly, HRT, referring to either estrogen alone or combined with 
progesterone treatment, is the most effective way to control menopausal symptoms, 
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particularly vasomotor symptoms and urogenital symptoms. The frequency of vasomotor 
symptoms are usually ameliorated within 4 weeks after starting treatment and reach 
maximal effects by 3 months (157). HRT improves vaginal symptoms by decreasing 
vaginal atrophy and increasing vaginal lubrication with topical oestrogen preparations 
(67).  But all these symptoms seem to recur if stopping treatment. Additionally, HRT is 
the first line medication for the prevention and management of osteoporosis and bone 
fracture in menopausal women who are under age of 50 years. Estrogen plus progestin 
combined HRT reduced the risk of total fracture by 24% and clinical vertebral and hip 
fracture by one third, compared to placebo (192).  
If the higher incidence of coronary heart disease (CHD) in postmenopausal 
females and females with bilateral oophorectomy is attributed to the lower estrogen 
level, then replacement of estrogen will decrease and prevent them from the disease. 
Based on this hypothesis, HRT is recommended to perimenopausal and postmenopausal 
women as primary or secondary CHD prevention since late 1980s.Supplemental 
estrogen improves cardiovascular functions by reversing all of these predictable 
detrimental effects with menopause, through improving high-density lipoprotein 
cholesterol and lipoproteins (1), inducing coronary and peripheral vasodilation, reducing 
vascular resistance (63) and improving endothelium functions. Many observational 
studies (26, 69, 84, 156, 198, 207, 208, 211, 212) have reported a reduction in the risk of 
coronary artery disease as well as in the mortality from cardiovascular disease and 
prolong life in postmenopausal women who receive HRT. A meta-analysis of 25 studies 
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shows approximately 30% decrease in the risk of CHD in HRT users (11), which 
strongly supports the cardiovascular protective effects of estrogen.  
 
1.3.4 Deleterious effect of HRT 
However, the reduction of coronary artery disease in postmenopausal women 
taking the estrogen therapy might have been caused by some biases which existed in 
these observational studies (10, 155, 174).  Postmenopausal estrogen users usually are 
well educated and healthier, which offers more protection form heart diseases; they have 
a better control of risk factors and receive more physician visits for regular follow-up 
and prescription renewals (10). Therefore, randomized clinical trials may eliminate these 
biases and give a more accurate estimation of the efficacy and safety of HRT as a 
prevention of coronary artery disease in postmenopausal women. Unfortunately, more 
and more randomized clinical trials are rejecting the concept of HRT used in these 
observational studies. 
Early in 1998, Heart and Estrogen/progestin Replacement Study (HERS) 
research group reported that there is no statistically significant improvement between the 
HRT group and placebo group in any of the cardiovascular outcomes and other end 
points including fracture, cancer and total mortality (205). More of the women in the 
HRT group experienced higher rates of coronary artery events, venous thromboembolic 
events and gallbladder diseases starting from year 1 (205). In 2002, Women’s Health 
Initiative enrolled more than 100 thousand women in a series of clinical trials and 
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assessed the major health benefits and risks of HRT (192). The benefits of estrogen 
alone or combined with progesterone were not considered to be sufficient enough to 
outweigh the risks, that HRT even increases the risks of heart attacks, strokes, invasive 
breast cancer and thrombosis (192). Following this, many clinical trials also reported 
similar observational evidences. Table 1 is a summary of these studies. 
 
1.3.5 Selective Estrogen Receptor Modulators (SERMs) and Selective Estrogen 
Receptor Down-regulators (SERDs) 
Selective estrogen receptor modulators (SERMs) are a class of synthetic non-
steroidal compounds exhibit estrogen receptor agonist or antagonist activity depending 
on the types of tissue. The first generation of SERM, tamoxifen, has been in use since 
1966 for breast cancer and has been approved as the drug of choice for the estrogen 
receptor-positive breast cancer since 2000 (163). The second generation of SERM, 
raloxifene, was developed as an alternative treatment of postmenopausal osteoporosis 
and breast cancer (137). The other SERMS, including toremifine, drolocifene, idoifene, 
lasofoxifene, arzoxifene et al., are the third generation and can be used in 
postmenopausal women with osteroporosis and/or vasomotor symptoms. Selective 
estrogen receptor down-regulators (SERD) are a group of SERMs that are pure estrogen 
antagonists, such as fulvestrant (ICI182,780). Prior to the Women’s Health Initiative 
trial, SERMs were commonly used as a substitute for HRT, but now the use of SERMs 
has been limited due to significant side effects. 
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1.3.6 Other medications for postmenopausal females 
Anti-lipids - statins 
Many studies have reported that an elevated risk of cardiovascular disease is 
associated with increased level of low-density lipoprotein cholesterol. Thus, statins, 
HMG-CoA reductase inhibitors which block the production of cholesterol in liver, is the 
most effective drug for primary (high cholesterol but without CHD) or secondary (early 
stage of CHD) prevention of CHD. As secondary prevention,  long-term use of statins 
showed 60% reduction in the number of cardiovascular events (including heart attack 
and sudden cardiac death) and 17% decrease in the risk of stroke (118). Additionally, 
statins increase bone mineral density and bone formation in postmenopausal women 
with hypercholesterolemia, and lower 30-40% of the risk of osteoporosis-related fracture 
(52). Nevertheless, the harmful effects associated with statin use as primary prevention 
in postmenopausal women may overweigh its benefits. First, Women Health Initiative 
observes that statins deteriorate glucose tolerance and produce a 48% greater risk of 
diabetes mellitus (40), which are high risk factors for cardiovascular disease. Secondly, 
cholesterol synthesis is essential in neuronal repair. Thus, lipophilic statins, which 
crossed the blood-brain barrier freely, accelerated the decline of cognitive function in 
patients with Alzheimer disease (193). Lastly, statins only reduce cardiovascular events 
in men with no history of cardiovascular disease but not in women (175). 
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Anti-inflammation and anti-platelets medication - aspirin 
Inflammation is involved in all the stages of atherosclerosis from initiation 
throughout the progression via oxidation of low-density lipoprotein (LDL). Oxidized 
LDL induces the expression of proinflammatory cytokines which induces migration of 
inflammatory cells such as macrophages, and accumulation of fatty streaks in the 
vascular walls (123). In addition,  platelets accelerate the progress of atherosclerosis by 
releasing the inflammatory factors and facilitating inflammatory cells migration towards 
the lesion sites (124). Therefore, aspirin, as an anti-inflammatory mediator and an anti-
platelet factor, has been used for primary and/or secondary prevention of cardiovascular 
disease among women and men. The Women Health Study (WHS) evaluated aspirin as 
primary prevention of major cardiovascular events in 39876 healthy postmenopausal 
women > 45 age and showed a 9% reduction in myocardial infarction and 24% reduction 
in ischemic stroke in women with low dose of aspirin (188). Aspirin also prevents 
certain cancers. For example, aspirin lowers 21% of melanoma among postmenopausal 
Caucasian women (61). However, there are some severe side effects associated with the 
use of aspirin. For example, gastrointestinal hemorrhage increases 40% and the 
hemorrhagic stroke increases 24% in aspirin users (188). Besides, dual anti-platelet 
therapy with aspirin and clopidogrel (another oral antiplatelet agent) in patients with 
stable CHD increases maximal platelet reactivity and aggravates the formation of 
atheroma (19). 
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High risk disease medications - ACE inhibitors and β-blockers 
One of the major factors associated with cardiovascular diseases in 
postmenopausal women is the increased level of angiotensin receptors, which attributes 
to systemic vascular constriction and increase of blood pressure. Angiotension-
converting enzyme (ACE) inhibitors interfere with the formation of angiotensin, lower 
blood pressure and reduce the chances of heart attack. β blockers, which block β-
adrenergic receptors and the effects of epinephrine, slow down the heart rate and lower 
blood pressure. Long-term administration of captropril, an ACE inhibitor, reduces more 
than 30% of the risk of myocardial infarction in hypertensive patients (222). A 23% 
more reduction of  second myocardial infarction after a first heart attack has been shown 
in patients of long term use of β-blockers (59). Furthermore, ACE inhibitors reverse 
oxidative stress and endothelial dysfunction in ovariectomized female rats, providing the 
evidence that ACE inhibitors may be beneficial in postmenopausal women (237). 
However, besides the common side effects including hypotension and hyperkalemia, 
both ACE inhibitors and β-blockers may increase the recurrence of breast cancer (62). 
ACE inhibitors may also raise the risk of bleeding in postmenopausal women by 
stimulating the release of basal vascular tissue plasminogen activator (tPA) through 
increased endogenous bradykinin (178). Additionally, in postmenopausal women with 
coronary heart disease, β blockers increase fragility fractures (204). 
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Diet supplements 
Although diet antioxidant supplements, such as OMEGA-3 fatty acids are the 
most commonly used means for people to protect their hearts. Until now, no randomized 
trials have demonstrated their cardiovascular benefits in primary or secondary 
prevention of cardiovascular events (7). 
To summarize, currently there is no ideal medication for primary or secondary 
prevention of cardiovascular events in postmenopausal women. And it is extremely 
urgent to find such a new compound that better targets estrogen signaling and be used 
ina variety of clinical situations,  thus provides new strategies not only for treatment of 
vascular diseases but of a broad range of estrogen-related diseases. 
 
1.4 G-PROTEIN COUPLED ESTROGEN RECEPTOR 1 (GPER) 
1.4.1 The discovery of GPER 
G protein-coupled estrogen receptor 1 (GPER), formerly known as G protein-
coupled receptor 30 (GPR30), is a G protein-coupled seven transmembrane estrogen 
receptor. It is first identified as a member of G protein coupled receptor (GPCR) and 
encoded by the Gper gene in late 1990s (28, 162).Then, in 1997, Carmeci et al. (28) 
reported the strong homology of GPR30 in both estrogen receptor-positive breast 
carcinoma cell line (MCF-7) and estrogen receptor-negative cell line (MDA-MB-231), 
indicating GPR30 may be involved in the physiological responses of estrogen-target 
tissues. In 2000, several groups investigated the functional role of GPR30 and 
demonstrated the possible link between GPR30 and the functional responses to estrogen 
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(54, 55). However, not until 2005, GPR30 was well accepted as G protein-coupled 
estrogen receptor 1 (GPER), based on the evidence that GPR30 directly binds estrogen 
and initiates responses with 10 fold higher binding affinity than that of ERα, provided 
almost simultaneously by Thomas et al. (216) and Revankar et al.(187). 
 
1.4.2 Subcellular localization of GPER 
The subcellular localization of GPER is still controversial. It has been reported 
that GPER is only localized in the endoplasmic reticulum; however, it is also evidenced 
that GPER is present in both the endoplasmic reticulum and the plasma membrane. 
Filardo et al. (53) showed the expression of GPER on the surface of GPER-transfected 
HEK293 cells by both fluorescence and confocal microscopy and the same finding was 
made by Funakoshi et al. (60). In contrast, there is a report that shows GPER is present 
only on the endoplasmic reticulum, therefore, can only be activated by cell-permeable 
GPER agonist (187). 
 
1.4.3 Ligands of GPER 
Estrogen definitely activates G protein-coupled estrogen receptor but with little 
receptor specificity because it binds to all three estrogen receptors: ERα,ERβ and GPER. 
Fulvestrant (ICI 182,780), a SERD, as a pure classical antagonist of ERα and ERβ, 
interestingly exhibits agonistic activity on GPER (181). Tamoxifen (187) and raloxifene 
(119), the SERMs, also have been reported to be GPER agonists. Furthermore, 
estrogenic compounds synthesized from plants (phytoestrogens) exhibit activation of 
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ERα/ERβ as well as GPER (129). In 2006, the first GPER-specific agonist G-1 was 
identified for its high affinity for GPER with no binding to the classical estrogen 
receptors, ERα and ERβ (21). Based on current evidences, G-1 is the most selective 
agonist for studying  the functional role of GPER. 
 
1.4.4 GPER actions on regulation of vascular tone 
Several studies have reported GPER protein expression in the cardiovascular 
system, including heart (115), arteries (76), in endothelial cells (91) as well as smooth 
muscle cells (76). 
It has been reported that activation of GPER induces relaxation of both conduit 
arteries and resistance arteries in different species. The selective GPER agonist, G-1, 
directly relaxes isolated mesenteric arteries and aortic rings from mREN2 Lew is female 
rats (125), rat middle cerebral artery (172), porcine coronary arteries (143) and human 
internal mammary arteries (75), and the vasodilatory effect can be blocked by the GPER 
selective antagonist G15 (125). The maximal relaxation of porcine coronary arteries 
induced by G-1 is 40%-50% in vitro. Meyer et al. (143) reports a maximal relaxation of 
38 ± 5 % mediated by GPER agonist G-1, which is consistent with the maximal 44.5 ± 
3% relaxation of porcine coronary arteries by 3 μM G-1 demonstrated by our previous 
work (234).  It is observed that both nitric oxide dependent and independent pathway are 
involved in G-1 mediated relaxation porcine coronary artery. We reported that G-1 
treatment induces endothelium-denuded porcine coronary artery relaxation and the NO 
synthase inhibitor L-NAMA has no effect on the response of the artery to G-1 (235). 
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However, Meyer et al. show reported that L-NAME may  completely abolish the dilatory 
response induced by G-1 (143). Furthermore, infusion of G-1may remarkably lower 
acute blood pressure in normotensive Sprague-Dawley rats in a dose-dependent manner 
(75) and chronic systolic blood pressure in ovariectomized hypertensive mRen2.Lewis 
female rats (127). 
However, there is also contradictory vascular effects of G-1 have been reported. 
Evidence suggests that estrogen potentiates Angiotensin II induced constriction via 
transactivation of GPER and epidermal growth factor receptor (EGFR) in human 
coronary microarteries (12).  G-1 induces vasoconstriction in basal perfusion pressure 
and induces vasodilation when the perfusion pressure is elevated by phenylephrine in the 
isolated perfused rat kidney (114). Besides, my unpublished data  also suggest that 
activation of GPER enhances endothelin-1 induced vasoconstriction effect in female rats 
aorta. Together, these evidences suggest that activation of GPER may primarily promote 
vasodilation, but with a component of vasoconstriction effect.  
 
1.4.5 GPER actions on endothelium 
Endothelium functions as a selective barrier between the bloodstream and vessel 
lumen and an important mechanism to maintain vascular homeostasis via release of 
multiply vasoactive factors (14). Endothelium also regulates vascular homeostasis by 
inhibiting inflammation, vascular smooth muscle cell proliferation and thrombosis (14). 
Endothelium dysfunction in many pathogenic states such as aging, hypertension and 
coronary heart disease is characterized as imbalance between vasodilators and 
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vasoconstrictors, reduction in NO bioavailability and alteration of anti-inflammatory 
effects (73, 85), thus serving as a good predictor of cardiovascular disease. 
Activation of GPER may promote endothelium function through increasing NO 
bioavailability and improving anti-inflammatory effects. For example, activation of 
GPER increases NO synthesis by enhancing phosphorylation of endothelial nitric oxide 
synthase (eNOS) in diabetic ovariectomized rats (122) and male Wistar rat (58). In 
addition to stimulating eNOS, GPER also regulates the release of other vasoactive 
molecules. In GPER-deficient rats, high dose of acetylcholine ≥0.1 μM is observed to 
stimulate the release of endothelium-derived constricting factors (EDCF) and induce 
stronger contraction comparing to wild type rats (142), suggesting that activation of 
GPER may attenuate the release of EDCF. Furthermore, it is reported that GPER 
decreases cell number in mouse brain microvascular endothelial bEnd.3 cells (91) and 
stimulates aldosterone induced endothelial cell apoptosis in primary cultured rat aortic 
endothelial cells (72), suggesting an important role of GPER in balancing the endothelial 
cell proliferation and preventing excessive proliferation. GPER also reduces the 
inflammatory cytokine tumor necrosis factor (TNF) actions on pro-inflammatory 
proteins, for example intercellular cell adhesion molecules-1 and vascular cell adhesion 
molecules-1; this effect is completely abolished by the selective GPER antagonist G-15 
(31). These findings suggest that GPER may exert anti-inflammatory and anti-
atherogenic effects on endothelium. 
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1.4.6 GPER actions on vascular smooth muscle  
Vascular smooth muscle composes the major part of vessel walls and regulates 
the redistribution of blood by changing the volume of vessels through 
contraction/relaxation, as above discussed  that activation of GPER relaxes both conduit 
artery and resistance artery tone; and in the meanwhile contains vasoconstriction 
component. 
Normally, vascular smooth muscle (VSM) cells remain in contractile phenotype 
with no/little proliferation and express specific contractile markers such as smooth 
muscle myosin heavy chain and smooth muscle actin (170). When there is vascular 
injury, VMS cells initiate proliferation cycle and migrate into intima in response to 
cytokines, such as vascular cell adhesion molecules-1, secreted by damaged endothelial 
cells (170). The switch of contractile VSM cells to synthetic VSM cells plays a major 
role in many diseases including atherosclerosis, hypertension and restenosis. Recently, 
we reported that activation of GPER decreased proliferation of porcine and human 
coronary artery smooth muscle cells (SMCs) and completely inhibited migration of 
porcine coronary artery SMCs induced by serum (120). Haas et al. also showed the same 
observation that GPER reduces proliferation of human umbilical vein VMS cells (75). 
In the series studies of the dissertation, we used porcine left anterior descending 
coronary arteries, as well as porcine and human coronary artery smooth muscle cells to 
investigate the actions of GPER in coronary arteries and to explore the underlying 
mechanisms by which GPER contributes to relaxation and constriction.  
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*Reprinted with permission from “Activation of G protein-coupled estrogen receptor induces 
endothelium-independent relaxation of coronary artery smooth muscle” by Yu X, Ma H, Barman SA, 
Liu AT, Sellers M, Stallone JN, Prossnitz ER, White RE, Han G, 2011. American Journal of Physiology 
-Endocrinology and Metabolism, 301(5), E882-888, Copyright [2011] by American Physiological 
Society.  
CHAPTER II 
ACTIVATION OF G PROTEIN-COUPLED ESTROGEN 
RECEPTOR 1 INDUCES ENDOTHELIUM-INDEPENDENT 
RELAXATION OF CORONARY ARTERY SMOOTH MUSCLE* 
 
2.1 INTRODUCTION 
Estrogen induces a rapid, nongenomic relaxation of coronary arteries in vitro (34, 
151) and can also enhance blood flow in intact hearts (160, 184). On the other hand, 
more recent studies indicate that estrogen can contract coronary arteries by increasing 
oxidative stress under certain conditions (226). Clinical trials indicate that estrogen 
replacement therapy (ERT) may increase the risk of coronary heart disease in 
postmenopausal women (192), thus limiting the utility of ERT. As an alternative, 
selective estrogen receptor modulators (SERMs) are increasingly being employed (197). 
However, the mechanism(s) of SERM action, especially in cardiovascular tissues, is 
largely unknown. SERMs and other estrogen-like compounds may function as either 
agonists, antagonists, or partial agonists of classic estrogen receptors (ERα and ERβ), 
and increasing evidence indicates that some of these compounds may also activate a 
more novel transmembrane estrogen-binding protein, G protein-coupled estrogen 
 25 
 
receptor 1 (GPER) (55, 181). 
Although studies have implicated GPER in mediating effects of estrogen on 
protein transcription and cell proliferation, the potential role of GPER in mediating 
nongenomic effects of estrogen in the vasculature remains to be established. Infusion of 
a selective GPER agonist (G-1) reduced mean arterial pressure acutely in rats and 
relaxed human mammary arteries in vitro (75); however, a molecular effector 
mechanism underlying GPER-mediated vasorelaxation was not identified. Moreover, 
there is virtually nothing known about GPER signaling in coronary arteries. We now 
provide tissue and cellular evidence that GPER can mediate estrogen signaling in 
coronary arteries: endothelium-independent relaxation, which involves stimulation of 
large-conductance, calcium- (BKCa) and voltage-activated potassium channels expressed 
in coronary artery smooth muscle (CASM). These findings provide direct evidence that 
signaling via GPER activation can contribute to the vascular effects of estrogens and 
suggest a potential rationale for why some SERMs may offer benefits of traditional ERT 
with fewer potential side effects. 
 
2.2 MATERIALS AND METHODS 
2.2.1 Cell culture 
Human coronary artery smooth muscle cells (SMCs) were purchased from 
Cambrex and grown in phenol red free smooth muscle growth medium with 5% fetal 
bovine serum (FBS), as described previously (227). Steroid hormones and growth 
factors were removed from FBS by charcoal stripping. MCF-7 cells were purchased 
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from American Type Culture Collection. Porcine coronary arteries were isolated from 
fresh porcine hearts obtained from a local abattoir. Single CASM myocytes were 
isolated as described previously (225). Briefly, the media layer from fresh coronary 
arteries was dissected free from adventitia and gently shaken (37°C) for 30 min in a 
dissociation medium containing 45 μM papain, 4 mM dithiothreitol, and 0.2% bovine 
serum albumin. Cells were then dissociated by gentle trituration. Experiments were 
performed 6–8 h after isolation. 
2.2.2 Tension studies 
Porcine coronary arteries were obtained as described previously (226, 227). 
Briefly, left anterior descending (LAD) coronary arteries were dissected and cleaned of 
excess fat and connective tissue. Two to four 5-mm rings were obtained from each LAD 
and prepared for isometric contractile force recordings. To control for possible indirect 
effects of endothelium-derived vasoactive factors, the endothelium was removed 
physically by rubbing the intimal surface and tested by observing the absence of 
acetylcholine-induced relaxation of the initial stabilizing contraction. Rings were 
mounted on two triangular tissue supports, with one support fixed to a stationary glass 
rod and the other attached to a force displacement transducer. Isometric contractions or 
relaxations were recorded on a PC computer using MacLab software. The tissue bathing 
solution was the modified Krebs-Henseleit buffer (in mM): 122 NaCl, 4.7 KCl, 15.5 
NaHCO3, 1.2 KH2PO4, 1.2 MgCl2, 1.8 CaCl2, and 11.5 glucose, pH 7.2. The solution 
was oxygenated continuously (95% O2-5% CO2) and maintained at 37°C. Coronary 
artery ring preparations were equilibrated for 90 min under an optimal resting tension of 
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2 g, and fresh bath solution was added to the tissue chamber every 30 min to prevent 
accumulation of metabolic end products. After the initial equilibration, preparations 
were exposed to effective concentrations of a contractile agonist, i.e., 1 μM 
prostaglandin (PG)F2α, to insure stabilization of the muscles. Vasodilatory responses 
were calculated as the percent reduction in tension (i.e., relaxation) from the 
precontracted state. Pharmacological inhibitors were allowed to equilibrate with the 
arteries for ≥30 min prior to measurement of a complete G-1 concentration-response 
relationship (1–3,000 nM). One vessel was exposed only to the constrictor agent to 
control for potential fading of the contractile response. In addition, control responses to 
DMSO vehicle alone were also measured, and the slight relaxation response to higher 
concentrations of DMSO was substracted from responses to G-1. 
2.2.3 Patch-clamp studies 
Cell-attached and excised patch-clamp recordings on isolated coronary myocytes 
were performed as described previously (225, 227). Whole cell and cell-attached patch-
clamp recordings on single cells were performed as described previously (225). For 
perforated-patch, whole cell recordings, cells were placed in a recording solution of the 
following composition (in mM): 140 NaCl, 5 KCl, 2 MgCl2, 2 CaCl2, 20 HEPES, and 20 
glucose (pH 7.2). Patch pipettes (≤3 MΩ) were fabricated from capillaries by a P-2000 
laser pipette puller (Sutter Instruments). The tip of patch pipette was filled with a 
solution containing (in mM) 90 KCH3SO3, 40 KCl, 5 MgCl2, and 20 HEPES to 
approximate normal cellular [K
+
] and [Cl
−
] (pH 7.2 with KOH). The remainder of the 
pipette was back-filled with a similar solution to which 200 μg/ml amphotericin B 
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(diluted by sonication from a 50 mg/ml stock in dimethylsulfoxide) was added. Voltage 
clamp and voltage pulse generation was controlled with an Axopatch 200B patch-clamp 
amplifier (Molecular Devices). Data were acquired and analyzed with pCLAMP 10.0 
(Molecular Devices). Voltage-activated currents were filtered at 2 kHz and digitized at 
10 kHz. Capacitative and leakage currents were subtracted digitally. For cell-attached 
patch studies, the recording chamber contained the following solution (in mM): 140 KCl, 
10 MgCl2, 0.1 CaCl2, 10 HEPES, and 30 glucose (pH 7.4, 22–25°C). Patch pipettes (2–5 
MΩ) were filled with Ringer's solution (in mM): 110 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, 
and 10 HEPES. Voltage across the patch was controlled by clamping the cell at 0 mV 
with the high-concentration extracellular potassium solution. In experiments recording 
the potassium channel activity of inside-out patches, the bathing solution exposed to the 
cytoplasmic surface of the membrane consisted of the following (in mM): 60 K2SO4, 30 
KCl, 2 MgCl2, 0.16 CaCl2, 1 BAPTA (pCa 7), 10 HEPES, 5 ATP, and 10 glucose (pH 
7.4, 22–25°C). The pipette solution was the same Ringer's solution described above. 
Average channel activity (expressed as number of channels × single-channel open 
probability; NPo) in patches with multiple BKCa channels was determined as described 
previously (225). NPo calculations were based on 10–15 s of continuous recording 
during periods of stable channel activity. Although channel activity was observed at a 
variety of membrane potentials, most single-channel data were analyzed at a potential of 
+40 mV, where BKCa channel openings are easily distinguished from other channel 
species to permit more accurate statistical analysis (77). 
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2.2.4 RT-PCR 
Total RNA was extracted from human CASM cells and MCF-7 cells and porcine 
coronary arteries using the TRI reagent (Sigma-Aldrich). Deoxyribonuclease 1 was used 
in the extracts to remove any genomic DNA contamination. QiagenOneStep RT-PCR kit 
was used in this study. The sequences of the primers for GPER were as follows: porcine 
coronary arteries, sense 5′-GTGGCCGACTCCCTGATCG-3′ and antisense 5′-
CGGGCATGGTGCTTGGTGC-3′ (product size is 200 bp) (27); human coronary artery 
SMCs, sense 5′-GGCTTTGTGGGCAACATA-3′ and antisense 5′-
CGGAAAGACTGCTTGCAGG-3′ (product size is 679 bp). PCR was performed for 40 
cycles in an Eppendorf Mastercycler Gradient (Eppendorf, Hamburg, Germany): 94 for 
1 min, 55 for 1 min, and 72 for 1 min. β-Actin primers (sense 5′-
AGTCCTGTGGCATCCACGAAACTA and antisense 
ACTGTGTTGGCGTACAGGTCTTTG) were used as internal standard (121). The PCR 
products were analyzed on 1.5% agarose gel and stained with ethidium bromide. 
2.2.5 Western blot 
Western blotting analysis was used to detect GPER. After being cleaned of 
excess fat and connective tissue and having endothelium removed by rubbing the intimal 
surface, LAD coronary arteries were snap-frozen in liquid nitrogen, pulverized (Fisher 
Scientific), and then lysed in homogenization buffer of the following composition: 50 
mM Tris·HCl, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% SDS, 1% NP-40, and 0.1% 
deoxycholic acid. Human CASM cells and MCF-7 cells were harvested and 
homogenized in the same solution. Protein concentrations were determined by Bio-Rad 
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DC protein assay and separated on SDS-polyacrylamide gels with a Mini Protean II 
(Bio-Rad) gel kit according to the manufacturer's instructions. Proteins were then 
transferred to Hybond enhanced chemiluminescence (ECL) membrane (Amersham 
Pharmacia Biotech) with a Mini-Trans-Blot Electrophoretic Transfer Cell (Bio-Rad) at 
100 V for 1 h. Membranes were blocked with 5% nonfat milk for 1 h at room 
temperature and then rinsed with Tris-buffered saline-Tween (TBST) three times for 15 
min. Membranes were then probed with GPER primary antibody (Santa Cruz 
Biotechnology) in TBST containing 5% nonfat milk protein for overnight at 4°C. After 
washing, the membranes were then incubated with anti-rabbit IgG conjugated to 
horseradish peroxidase and visualized with an ECL system (Amersham). The 
membranes were stripped and then immunoblotted with β-actin antibody (Sigma-Aldrich) 
for protein loading control. 
2.2.6 Statistical analysis 
Data were expressed as means ± SE. Significance between two groups was 
evaluated by Student's t-test for paired data. Comparison between multiple groups was 
made by analysis of variance. Probability of <0.05 indicated a significant difference. 
2.2.7 Materials 
Antibodies were purchased from Santa Cruz Biotechnology, and G-1 was 
purchased from Calbiochem. All other chemicals were purchased from Sigma-Aldrich. 
Primers were purchased from Integrated DNA Technologies. 
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2.3 RESULTS 
2.3.1 GPER mediated coronary artery relaxation 
GPER is activated by 17β-estradiol and other estrogen-like compounds; however, 
the cardiovascular effects of these agents are poorly understood. To better target and 
identify the effects of GPER stimulation in CASM, we measured relaxation of 
endothelium-denuded porcine coronary arteries in response to G-1, which exhibits 
nanomolar affinity for GPER but does not bind ERα or ERβ(180). Endothelium-denuded 
coronary arteries were precontracted with 1 μM PGF2α, and cumulative addition of G-1 
produced a concentration-dependent relaxation in coronary arteries. On average, the 
maximal relaxation effect of G-1 was 44.5 ± 3.2% (3 μM, n = 23; Fig. 4A) with an 
average EC50 of 6.28 × 10
−8
 M. We then verified the specificity of action on GPER by 
employing a selective GPER inhibitor, G15 (43). Pretreating arteries with 3 μM G15 
significantly attenuated G-1-induced relaxation at all G-1 concentrations above 1 nM 
(Fig. 4C). The average maximal G-1-induced (3 μM) relaxation was reduced nearly one-
half (10.5 ± 2.0%, n = 21, P < 0.003) by G15 treatment; however, there was no 
significant change in EC50 value (5.2 × 10
−8
) in the presence of G15. However, parallel 
studies indicated a minor relaxation effect in the presence of solvent (DMSO) alone (Fig. 
4A, top curve). Care was taken to assure that the total concentration of DMSO never 
exceeded 0.1% at any time. Therefore, to obtain a more accurate response to G-1, the G-
1 concentration-response relationship was normalized by subtracting out this control 
component, and the resulting G-1 concentration-response relationship is illustrated in Fig. 
4B. 
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Figure 4. Stimulation of G protein-coupled estrogen receptor 1 (GPER) relaxes 
endothelium-denuded, precontracted coronary arteries. A: complete concentration-
response relationship for G-1-induced relaxation. Each point represents the mean 
relaxation effect ± SE (n = 29). Top curve is a control concentration-response 
relationship in the presence of solvent (DMSO) alone (n = 6). B: actual G-1-induced 
relaxation response after normalization by subtracting the control component. C: 
complete concentration-response relationship for G-1-induced relaxation in the presence 
or absence of G15, a GPER antagonist. Each point represents the mean relaxation effect 
± SE (n = 21). *P < 0.05. 
 
2.3.2 GPER expression in coronary artery smooth muscle cells 
Molecular experiments were done to confirm GPER expression in CASM. RT-
PCR studies employed primers for both porcine and human GPER. RT-PCR results 
demonstrated that high levels of GPR30 mRNA expression were detected successfully in 
both human and porcine coronary artery SMCs (n=3; Fig.5) together with β-actin (data 
not shown). These findings are the first to report GPER mRNA expression coronary 
artery. Previous studies demonstrated that MCF-7 breast cancer tumor cells express 
GPER (55), and these cells were employed as a positive control for GPER mRNA in 
each study. In addition to these RT-PCR studies, immunoblotting experiments detected 
expression of an ∼38-kDa GPER protein in CASM from either porcine or human 
coronary artery SMCs (n=3; Fig.5B). GPER expression in MCF-7 cells was again 
employed as a positive control. 
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Figure 5. Coronary artery smooth muscle cells (SMCs) express GPER. A: GPER 
mRNA is expressed in porcine and human coronary artery smooth muscle cells 
(CASMC). RT-PCR products from MCF-7 cells were employed as positive controls. B: 
Immunoblot detection of GPER protein expression in coronary myocytes from either 
porcine (P) or human (H) arteries (n=3). MCF-7 cells were employed as positive 
controls. β-actin was employed as a control for protein loading. 
 
2.3.3 BKCa channel activity involved in NO independent coronary artery relaxation 
We had demonstrated previously that estrogen-induced relaxation of CASM (via 
ERα) involves nitric oxide (NO) production and activation of the large-conductance 
BKCa channel (80). In contrast, inhibiting NO signaling had no effect on G-1-induced 
coronary artery relaxation. Inhibition of NO synthase (NOS) activity with N
ω
-nitro-L-
arginine methyl ester (L-NAME; 100 μM) did not attenuate G-1-induced coronary artery 
relaxation significantly at any concentration (P>0.05, n=6; Fig. 6A). In addition, G-1-
induced relaxation was unaffected by pretreating arteries with 10 μM1H-
[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one, a selective inhibitor of guanylyl cyclase 
activity (n=5; data not shown). However, similar to 17β-estradiol, the relaxation effect of 
G-1 was dependent upon potassium efflux from CASM cells. G-1-induced coronary 
artery relaxation was inhibited by 100 nM iberiotoxin, a highly selective inhibitor of 
BKCa channels (195). After the data were normalized by controlling for vehicle effects, 
iberiotoxin inhibited G-1-induced relaxation (1 μM) by an average of ∼65% [control 
18.7 ± 1.4, iberiotoxin (IBTx) 6.8 ± 1.3%, n=5, P=0.001; Fig.6B]. A completely 
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normalized concentration-response relationship for G-1-induced relaxation in the 
absence and presence of 100 nM IBTx is illustrated in Fig. 6C and indicates a significant 
inhibition of G-1-induced relaxation at all concentrations >10 nM (n=9). 
 
 
 
 
Figure 6. GPER-mediated coronary artery relaxation is nitric oxide independent and 
involves large-conductance, calcium-activated potassium (BKCa) channel activity. A: 
pretreating (30 min) coronary arteries with 100 μM Nω-nitro-L-arginine methyl ester (L-
NAME) to inhibit nitric oxide synthase had no effect on G-1-induced relaxation. Each 
bar represents the mean ± SE (n=6). B: pretreating vessels (30 min) with 100 nM 
iberiotoxin (IBTx; 30 min; n=5) attenuated 1 μM G-1-induced relaxation significantly 
(*P = 0.001). C: complete concentration-response relationship for G-1-induced 
relaxation in the absence or presence of 100 nM IBTx (n=5). *P < 0.05 or lower. con, 
control. 
 
2.3.4 Identification of GPER stimulation on BKCa channels 
To more directly identify a stimulatory effect of G-1 on BKCa channels, single-
channel patch clamp experiments were performed. In cell-attached patches on intact 
porcine CASM myocytes, we observed that membrane electrical activity was dominated 
by a large-conductance, outwardly conducting channel that we have identified 
previously as the BKCa channel in these same cells (225, 227). As illustrated in Fig. 7A, 
we observed rather minimal activity of BKCa channels under control conditions (25–
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28°C, +40 mV). In contrast, BKCa channel activity increased dramatically after cells 
were treated with 100 nM G-1. On average, G-1 increased BKCa channel activity from an 
NPo of 0.006 ± 0.002 to 0.313 ± 0.092 (n=4, P<0.03). A time course plot of 
BKCa channel activity is illustrated in Fig.7.We confirmed the identity of this molecule 
as the BKCa channel by measuring activity of excised inside-out membrane patches from 
porcine CASM myocytes (Fig.7B). Under physiological concentrations of calcium (100 
nM) at the cytoplasmic surface of the membrane, channel activity was minimal. In 
contrast, when [Ca
2+
]i was raised to 100 μM, there was a dramatic increase in channel 
opening (Fig. 7B, middle). On average, channel NPo was increased from 0.001 ± 0.001 
to 0.684 ± 0.178 (n=3, P<0.05) by increasing [Ca
2+
]i. Furthermore, subsequent addition 
of 1 mM tetraethylammonium (TEA) abolished calcium-stimulated channel activity 
(Fig. 7B, right). At concentrations of 1 mM or less, TEA exhibits selectivity for 
blockade of BKCa channels. 
 
 
 
 36 
 
Figure 7. G-1 stimulates BKCa channel activity in porcine coronary artery SMCs. A: 
typical recordings from the same cell-attached patch (+40 mV) before (con) and 20 
minutes after application of 100 nM G-1. Upward deflections indicate channel opening 
from the closed state (dashed line). Right: activity histogram of BKCa channel open 
probability (NPo) before and 20 minutes after application of 100 nM G-1. Total 
recording time under each condition was 12–14 s. Break in the time axis represents drug 
incubation. B: typical recordings from the same excised inside-out patch from a porcine 
coronary artery SMCs with either 100 nM (left) or 100 μM (middle) [Ca2+] exposed to 
the cytoplasmic face of the membrane (+40 mV). Right: recording after subsequent 
addition of 1 m TEA to the cytoplasmic surface of the membrane (100 μM [Ca2+]). 
 
We further confirmed the ability of G-1 to open a BKCa channel in CASM by 
observing a stimulatory effect of G-1 in myocytes from human coronary arteries (human 
CASM). As illustrated in Fig. 8A, addition of 100 nM G-1 to a cell-attached patch on a 
human CASM cell increased channel activity substantially. On average, channel activity 
increased from an NPo of 0.012 ± 0.004 to 0.027 ± 0.003 (n=3, P=0.05; Fig. 8, right). In 
contrast to these experiments on intact myocytes, G-1 was unable to stimulate 
BKCa channels isolated in a cell-free, inside-out patch (Fig.8B). When we excised the 
membrane patch into the microscope chamber, the cytoplasmic surface of the patch was 
immediately exposed to a supra physiological level of calcium (100 μM). As expected, 
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this resulted in a dramatic increase channel activity, confirming that this protein is 
indeed the BKCa channel that we have characterized extensively in these same cells 
previously (227, 240). When [Ca
2+
] was subsequently lowered to a more physiological 
100 nM, channel activity immediately decreased as expected. However, in contrast to 
what we observed in cell-attached patches, addition of 100 nM G-1 to this excised patch 
had no effect on BKCa channel activity (Fig. 8B, right). These experiments provide direct 
evidence that excludes potential effects of G-1 directly on the BKCa channel protein and 
demonstrate the necessity of an intact cellular transduction mechanism. 
 
 
 
Figure 8. G-1 stimulates BKCa channel activity in human coronary artery SMCs. A: 
recordings (+40 mV) from the same cell-attached patch on human coronary artery SMCs 
before (control) and 25 min after addition of 100 nM G-1. Upward deflections indicate 
channel opening from the closed state (dashed line). Right: average increase in 
BKCa channel activity (NPo) stimulated by G-1. Bars represent the average of 3 
membrane patches ± SE. B: recordings from the same excised inside-out patch from 
human coronary artery SMCs. Upward deflections indicate channel opening from the 
closed state (dashed line). Left: BKCa channel activity in the presence of high calcium 
(100 μM) at the cytoplasmic surface of the patch. Middle: channel activity recorded after 
calcium levels were lowered to 100 nM. Right: G-1 (100 nM) had no effect on channel 
activity in excised patch. *P < 0.05. 
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2.4 DISCUSSION 
Recent studies suggest that GPER, a nonclassic, membrane-associated, estrogen-
binding protein, may mediate rapid estrogen signaling in certain cell types (181); 
however, the role of GPER in mediating estrogen responses is controversial. For 
example, GPER-deficient mice exhibit a normal reproductive phenotype, indicating a 
nonessential role for GPER in mediating hypothalamic-pituitary-gonadal function (167). 
In contrast, other studies indicate an important if not essential role for GPER in 
reproductive function. Inhibition of GPER mRNA and protein expression markedly 
suppresses estrogen-stimulated follicle formation in hamster ovary (223), and estrogen-
stimulated proliferation of mouse sperm cells is mediated via GPER (199). Thus, the 
physiological role of GPER remains unclear, and even less is known of a potential role 
for GPER in cardiovascular function. Although GPER mRNA has been detected in 
human blood vessels (76), we know little of its function and cellular/molecular 
transduction mechanisms in the cardiovascular system. 
G-1 is reported to be a GPER agonist that exhibits nanomolar affinity for GPER 
but does not bind ERα or ERβ (180). We had demonstrated previously that ICI 182,780, 
a nonselective ER antagonist, relaxes porcine coronary arteries in vitro by an 
endothelium-independent mechanism (79). Meyer et al. (143) have also reported that G-
1 and ICI 182,780 relaxed porcine epicardial coronary artery rings, but the mechanism of 
G-1 action was not investigated in detail in this study. The present results now 
demonstrate that G-1 induces endothelium-independent relaxation of coronary arteries 
and that this response is attenuated by G15 (selective GPER antagonist). These studies 
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strongly suggest that activation of GPER in CASM causes relaxation. Furthermore, our 
functional studies are supported by RT-PCR and immunoblot experiments verifying 
expression of GPER in both porcine and human CASM. Taken together, these findings 
implicate a role for GPER in mediating acute estrogen and/or SERM action on CASM 
and hence, cardiac blood flow. Support for this mechanism is gained from prior studies 
indicating GPER mRNA expression in smooth muscle from human internal mammary 
arteries and saphenous veins (76) and findings that G-1 administration lowers blood 
pressure in vivo (75). Therefore, accumulating evidence indicates a novel, nongenomic 
mechanism mediating the effect of estrogens on coronary arteries, i.e., signaling via a G 
protein-coupled receptor that does not involve activation of either ERα or ERβ. It is 
unknown whether our findings on GPER signaling in CASM can be extended to 
coronary endothelium, which is also a target tissue of estrogen action. 
Signaling mechanisms downstream to GPER activation in CASM remain to be 
elucidated. We have reported that estrogen-induced coronary artery relaxation involves 
generation of NO in both porcine and human CASM (42, 225, 227). In contrast, we 
found that inhibiting NOS activity in coronary arteries with L-NAME had no effect on 
G-1-induced relaxation. Moreover, inhibiting the activity of guanylyl cyclase (a primary 
target for NO signaling) also had no effect on responses to G-1. Taken together, these 
findings indicate a NO-independent mechanism of action for G-1/GPER in CASM. 
These findings are consistent with our previous report that ICI 182,780 does not 
stimulate NO production in CASM (80). Therefore, we conclude that GPER-mediated 
relaxation of CASM, unlike 17β-estradiol-stimulated coronary artery relaxation via ERα, 
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is not dependent upon NO production. The fact that GPER-induced relaxation was 
endothelium independent further supports the idea that NO was not involved in this 
response. However, similar to 17β-estradiol, we found evidence that GPER activation 
leads to stimulation of BKCa channel activity in CASM. 
Our tension studies demonstrated that coronary artery relaxation induced by G-1 
involves potassium efflux. These findings implicate potassium channels in the vascular 
response to GPER activation. The fact that G-1-mediated relaxation was inhibited by 
iberiotoxin, which is a highly selective antagonist of BKCa channels, provides strong 
pharmacological evidence for involvement of this protein in GPER-mediated relaxation. 
Definitive evidence that GPER activation stimulates BKCa channel activity in CASM 
was then provided by single-cell, patch-clamp recordings on myocytes isolated from 
porcine and human coronary arteries. As we have reported in a number of previous 
studies (42, 79, 225), ion channel activity in CASM is dominated by a large-conductance 
(∼200 pS) potassium channel that is stimulated by cytoplasmic calcium and inhibited by 
iberiotoxin. This BKCa channel is a known target of estrogen action and is an important 
effector molecule that induces membrane repolarization and CASM relaxation. 
We found G-1 to be a powerful stimulator of BKCa channel activity in intact 
CASM myocytes from either porcine or human arteries. Interestingly, however, G-1 was 
ineffective at stimulating channels isolated in excised membrane patches. These findings 
provide direct evidence that the BKCa channel protein complex is not a functional 
substrate for G-1 binding. Rather, G-1 action on CASM requires an intact cellular 
signaling mechanism involving diffusible cytosolic and/or membrane-associated second 
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messenger compounds. Although we can find no previous patch-clamp studies that have 
employed G-1, there is a previous report that ICI 182,780 can stimulate BKCa channels 
in colonic smooth muscle cells (47). Therefore, we speculate that the effect of ICI 
182,780 in these nonvascular smooth muscle cells is also mediated via GPER. In light of 
these findings, it is becoming apparent that estrogen and estrogen-like compounds may 
stimulate distinct receptor proteins in CASM (e.g., ERα, ERβ, and/or GPER), but 
ultimately these transduction pathways appear to converge on a common effector protein, 
the BKCa channel. Thus, the present findings from intact arteries and isolated myocytes 
are entirely consistent with a novel, nongenomic mechanism of estrogen action in the 
cardiovascular system, i.e., activation of GPER, which relaxes CASM via stimulation of 
BKCa channel activity. We certainly have not excluded other potential signaling 
mechanisms for GPER but propose BKCa channel activity to be a likely downstream 
effector mediating GPER-induced coronary artery relaxation. 
In conclusion, because of increased cardiovascular risk associated with ERT, 
other estrogen-like compounds (e.g., SERMs) have been recommended as an alternative 
therapy (148). These compounds have a diversity of chemical structure and may have a 
unique and unpredictable array of clinical responses (197). The present study has 
demonstrated that, like estrogen, a nonsteroidal GPER agonist (G-1) relaxes 
endothelium-denuded coronary arteries. These studies indicate a novel, nongenomic 
estrogen-signaling mechanism in CASM, which we found to express GPER mRNA and 
protein. More conclusive proof of GPER involvement in these responses will require use 
of GPER-knockout mice, and future studies will certainly include such additional 
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measures. Nonetheless, the present studies suggest a common signaling mechanism for 
nongenomic estrogen action in CASM, i.e., stimulation of GPER leading ultimately to 
increased activity of BKCa channels and coronary artery relaxation. Unlike 17β-estradiol, 
this response does not appear to involve NO production, nor does it require activation of 
classic ERs. We propose that GPER activation can enhance coronary blood flow and 
thus may help protect against myocardial ischemia. This hypothesis is supported by a 
recent finding that G-1 is cardioprotective when administered to rat hearts in vitro (45), 
although this protection also involved GPER expressed in cardiac myocytes. In summary, 
these findings strongly support the caveat that estrogen-like compounds used for treating 
specific disease states (e.g., cancer) may also affect other organs and systems. 
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*Reprinted with permission from “G protein-coupled estrogen receptor 1 mediates relaxation of 
coronary arteries via cAMP/PKA-dependent activation of MLCP” by Yu X, Li F, Klussmann E, 
Stallone JN, Han G, 2014. American Journal of Physiology-Endocrinology and Metabolism, 307(4), 
E398-407, Copyright [2014] by American Physiological Society. 
 
CHAPTER III 
G PROTEIN-COUPLED ESTROGEN RECEPTOR 1 MEDIATES 
RELAXATION OF CORONARY ARTERIES VIA CAMP/PKA-
DEPENDENT ACTIVATION OF MLCP* 
 
3.1 INTRODUCTION 
Cardiovascular disease, especially coronary heart disease, is the leading cause of 
death among women in the US and exceeds breast cancer mortality in women of all ages 
(2, 230). Although premenopausal women have had less incidence of cardiovascular 
disease than men, by the late 1970s the risk of cardiovascular disease had equalized 
(214). Animal and observational studies have suggested female ovarian sex hormones to 
protect against cardiovascular dysfunction (168). For example, estrogen alone or in 
combination with a progestin has favorable effects on lipoproteins and fibrinogen (1), 
improves vascular inflammation (231), and restores endothelial function and nitric oxide 
release, thus promoting vasorelaxation (111). Estrogen can also act directly on smooth 
muscle cells to relax arteries (79, 80) and inhibit smooth muscle cell proliferation (217). 
Although this evidence strongly suggests that estrogen is indeed vasoprotective, 
randomized, controlled large trials of hormone replacement therapy such as the Women's 
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Health Initiative showed no cardiovascular benefit for estrogen or estrogen plus 
progestogen treatment (92, 134). These apparent conflicting findings warrant further 
mechanistic study of the effects of estrogen on the vasculature. 
The newly reported, membrane-associated G protein-coupled estrogen receptor 1 
(GPER; initially called GPR30) is structurally unrelated to nuclear ERα or ERβ (165, 
173, 187, 216). Membrane localization of GPER provides a novel mechanism for rapid, 
nongenomic responses to estrogen (82, 187). Evidence that GPER plays an important 
role in mediating important cardiovascular actions of estrogen is building (78, 126, 146, 
158). GPER activation relaxes rat carotid (24), rat aorta (127), human mammary arteries 
(75), and coronary arteries (143, 235) with or without endothelium, indicating that 
GPER acts directly on vascular smooth muscle to regulate vascular tone. The selective 
GPER agonist G-1 lowers blood pressure in either normotensive (75) or mRen2.Lewis 
hypertensive rats (127). Conversely, deletion of Gper increases blood pressure (135). G-
1 improves functional recovery from myocardial ischemia-reperfusion by reducing post-
ischemic contractile dysfunction and infarct size, reduces brain infarct size, and prevents 
stroke-induced immunosuppression in rats (45, 238). However, because of its novelty, 
the mechanism by which GPER mediates estrogen action is still unclear (117). 
Estrogen stimulates cAMP production in breast cancer cells via activation of 
GPER (216). Various phyto- and xenoestrogens also stimulate cAMP production via 
GPER either in breast cancer cells or in an ERα- and ERβ-negative cell line [human 
embryonic kidney (HEK)-293 cells] that was stably transfected with GPER (215, 216). 
Although estrogen-stimulated production of cAMP, a powerful vasodilatory signal, has 
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been demonstrated in rat aortic (48) and porcine coronary artery smooth muscle cells 
(SMCs) (105), the role of cAMP in response to GPER activation in coronary arteries is 
unknown. The key component of generating and sustaining vascular tone is the 
phosphorylation state of the smooth muscle contractile apparatus myosin light chain 
(MLC) (107). It has been reported that cAMP decreases MLC phosphorylation by 
activating the MLC phosphatase (MLCP) (4, 6); however, to the best of our knowledge, 
a potential link between estrogen, cAMP, and MLC has not been investigated. In this 
study described here, we tested the hypothesis that GPER activation induces coronary 
relaxation by activating MLCP via cAMP/PKA signaling. 
 
3.2 MATERIALS AND METHODS 
3.2.1 Cell culture 
Coronary arteries were dissected from porcine hearts obtained from a local 
abattoir, as described previously (226, 227), and the protocol was in compliance with the 
Texas A&M University Institutional Animal Use Protocol. The endothelial layer was 
gently removed with a cotton-tipped swab, and the media layer was dissected free from 
the adventitia. The medial layer was then enzymatically dispersed in a 25-cm
2
 tissue 
culture flask and gently shaken (37°C) in 10 ml of dissociation medium, containing (in 
mM) 110 NaCl, 5 KCl, 2 MgCl2, 0.16 CaCl2, 10 HEPES, 10 NaHCO3, 0.5 KH2PO4, 0.5 
NaH2PO4, 0.48 EDTA, 10 taurine, and 10 glucose plus 24 mg of elastase, 6 mg of 
collagenase, and 15% bovine serum albumin for 3 h. Cells were then dispersed by gentle 
trituration and centrifuged at 800 rpm for 5 min. The pellet was suspended with smooth 
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muscle cells medium SmGM (Lonza) and seeded in a 25-cm
2
 tissue culture flask coated 
with 1% gelatin. Human coronary artery smooth muscle cells (SMCs) were purchased 
from Life Technologies. Both human and porcine coronary artery SMCs were 
maintained in SmGM and kept at 37°C under 5% CO2 in a humidified incubator. The 
purity of coronary artery SMCs in culture was verified by positive staining with smooth 
muscle-specific α-actin (120). Passages 2 and 3 of porcine and passage 5 of human 
coronary artery SMCs were used in this study. 
3.2.2 Tension studies 
Left anterior descending coronary arteries were dissected from porcine hearts, 
trimmed of fat and connective tissue, and cut into rings (axial length ∼5 mm) for 
isometric contractile force recordings. Rings were endothelium denuded to eliminate 
effects of endothelium-derived vasoactive factors. Endothelium denudation was 
confirmed by the absence of relaxation to bradykinin (100 nM) exposure. Arterial rings 
were mounted in isometric myographs (Danish Myograph Technology) filled with 10-ml 
modified Krebs-Henseleit buffer (in mM): 122 NaCl, 4.7 KCl, 15.5 NaHCO3, 1.2 
KH2PO4, 1.2 MgCl2, 1.8 CaCl2, and 11.5 glucose, pH 7.2, bubbled with 95% O2-5% 
CO2 (pH 7.4) at 37°C. Two stainless-steel wires were guided through the lumen of the 
rings. One wire was connected to a force displacement transducer and the other to a 
stationary micrometer. The preparations were then allowed to equilibrate for 90 min in 
Krebs-Henseleit buffer. During the first 30 min, the arterial rings were gradually 
stretched until a stable tension of 20 mN was obtained, which was the optimal resting 
tension determined in preliminary experiments for these preparations. Isometric tension 
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was recorded on a PC computer using the LabChart data acquisition system (AD 
Instruments). After the initial equilibration, preparations were contracted three times 
with prostaglandin F2α (PGF2α; 1 μM) and then washed and allowed to relax to basal 
tension. Then preparations were exposed to PGF2α (1 μM) to induce a stable contraction. 
When the force reached steady state, G-1 was added in a cumulative manner by 
increasing the concentration in log increments. Relaxation responses were calculated as 
the percent reduction in tension at each G-1 concentration from the precontracted state. 
Pharmacological inhibitors were allowed to equilibrate with the arteries for ≥30 min 
prior to measurement of a complete G-1 or other vasodilators' concentration-response 
relationships. One ring in each set of experiments was exposed only to the constrictor 
agent PGF2α (1 μM) to control for potential fading of the contractile response. In 
addition, control responses to cumulative amounts of vehicle [dimethylsulfoxide 
(DMSO)] were measured by adding the identical amount of DMSO used for each 
concentration of G-1, forskolin, or 6-Bnz-cAMP. The total amount of vehicle never 
exceeded 0.1%. 
3.2.3 Western blot 
Standard Western blot analysis was used for detecting phosphorylation of 
myosin-targeting subunit protein-1 (p-MYPT-1), the regulatory subunit of MLCP, from 
porcine coronary artery tissue lysates and phosphorylation of MLC from porcine 
coronary artery SMC lysates. Arterial rings were prepared, mounted in the chamber of 
the myograph, equilibrated, and contracted three times by PGF2α (1 μM), as described 
above. Then preparations were pretreated with inhibitors and G-1 30 min before PGF2α 
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(1 μM) was added to induce contraction. Artery rings were collected when contraction 
reached plateau and were snap-frozen in liquid nitrogen. Tissues were pulverized (Fisher 
Scientific) and then lysed in homogenization buffer of the following composition: 50 
mM Tris·HCl, 0.1 mM EGTA, 0.1 mM EDTA, 0.1% SDS, 1% NP-40, and 0.1% 
deoxycholic acid. For MLC20 phosphorylation detection, porcine coronary artery SMCs 
were treated with drugs, as indicated in the results. Coronary artery SMCs were 
harvested and homogenized. Protein concentrations were determined by a detergent-
compatible protein assay (Bio-Rad). Proteins were separated by SDS-PAGE with a Mini 
Protean II (Bio-Rad) gel kit according to the manufacturer's instructions. 
Proteins were then transferred to Hybond enhanced chemiluminescence 
membrane (Amersham Pharmacia Biotech) with a Mini-Trans-Blot Electrophoretic 
Transfer Cell (Bio-Rad) at 100 V for 1 h. Membranes were blocked with 5% nonfat milk 
for 1 h at room temperature and then rinsed with Tris-buffered saline-Tween (TBST) 
three times for 15 min. Membranes were then probed with primary antibodies in TBST 
containing 5% nonfat milk protein for overnight at 4°C. The p-MYPT-1 was probed with 
Thr
853
 p-MYPT-1 primary antibody (Santa Cruz Biotechnology), p-MLC was probed 
with primary antibody p-MLC (Ser
19; Cell Signaling Technology), and β-actin (Santa 
Cruz Biotechnology) was used for protein loading control in the densitometry analysis. 
Experiments were performed in triplicate, and means ± SE were calculated and plotted. 
3.2.4 Cyclic AMP assay 
Cyclic AMP production was measured with a cAMP enzyme immunoassay kit 
according to the manufacturer's instructions (Cayman Chemical), as described 
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previously (240). Porcine coronary artery SMCs, passages 2–3, were cultured in 35-mm 
culture dishes in SmGM medium for 2 or 3 days. When cells reached 85–90% 
confluence, cells were serum-deprived for 18 h in phenol red-free α-MEM medium 
(Invitrogen). Cells were preincubated for 30 min at 37°C in buffer containing 3-isobutyl-
1-methylxanthine (100 μM) to inhibit phosphodiesterases. Then cells were treated with 
G-1 (10 nM to 1 μM), 0.1% DMSO was used as solvent control, and forskolin (1 μM) 
treatment was used as a positive control. 
3.2.5 PKA activity assay 
PKA activity was measured by applying the PepTag protein kinase assay 
(Promega) according to the manufacturer's instructions (20). Porcine coronary artery 
SMCs (passage 2) were cultured in 100-mm culture dishes in SmGM medium for 2 days. 
After being serum-deprived for 18 h, cells were treated with G-1 (100 nM) in the 
presence or absence of G-36 (1 μM) for 30 min; 0.1% DMSO was used as solvent 
control, forskolin (1 μM) was used as a stimulant to mediate PKA activation, and GPER 
agonist and antagonist were applied as described above. Cells were washed with 
phosphate-buffered saline and suspended in PKA extraction buffer provided in the assay 
kit. The crude extracts were assayed on the same day that they were prepared to retain 
maximal activity. The PKA-specific peptide substrate L-R-R-A-S-L-G (Kemptide) was 
used for measuring PKA activity. The phosphorylated Kemptide was separated from 
nonphosphorylated Kemptide by 0.8% agarose electrophoresis. The peptides were 
imaged under UV light. The image was scanned and quantified by densitometry using 
ImageJ. 
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3.2.6 RhoA activity assay and phsophorylation of RhoA detection 
RhoA activity was monitored by measuring changes in RhoA-GTP in cultured 
human and porcine coronary artery SMCs under drug treatments. Briefly, human 
(passage 5) and porcine (passage 3) coronary artery SMCs were seeded in 60-mm dishes. 
After 2 days of being grown in the SmGM medium, cells were serum-deprived for 18 h 
and then treated with drugs as indicated in the results. Cell lysates were collected and 
protein concentrations from each sample quantified and adjusted for RhoA activity assay 
and Western blotting. RhoA activity was measured with G-LISA RhoA activation assay 
biochem kit (Cytoskeleton) according to the manufacturer's instructions by detecting 
absorbance at 490 nm. RhoA phosphorylated at Ser
188
 by PKA was detected by Western 
blotting using specific antibodies. 
3.2.7 Materials 
Antibodies were purchased from Santa Cruz Biotechnology. G-1 was purchased 
from Calbiochem, and 8-(4-chlorophenylthio)adenosine 3′,5′-cyclic 
monophosphorothioate Rp-isomer (Rp-8-CPT-cAMPS) and N6-benzoyladenosine-3′,5′-
cyclic monophosphate (6-Bnz-cAMP) were from Biolog Life Science Institute. PKA 
inhibitor PKI (14-22) amide (myristoylated) is from Enzo Life Sciences. 3,3′-Diamino-
4,4′-dihydroxydiphenylmethane, 4,4′-methylenebis(2-aminophenol), and bis(3-amino-4-
hydroxyphenyl)methane (FMP-API-1) were obtained as described by Christian et al. 
(37). All other chemicals were purchased from Sigma-Aldrich. 
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3.2.8 Statistical analysis 
Data are expressed as means ± SE. Significance between two groups was 
evaluated by Student's t-test for paired data. Comparison between multiple groups was 
made by two-way ANOVA. P < 0.05 indicated a significant difference. 
 
3.3 RESULTS 
3.3.1 Cyclic AMP production and coronary relaxation 
We and others have reported that GPER activation induces a rapid relaxation of 
porcine coronary arteries (79, 143, 235). However, the downstream signaling events in 
this pathway have yet to be elucidated. GPER activation has been shown to stimulate 
cAMP production in breast cancer cells (216). We tested whether activating GPER with 
G-1 (10–1,000 nM) stimulated cAMP production in porcine coronary artery SMCs. G-1 
at every concentration significantly increased cAMP production compared with the 
DMSO solvent control group (P < 0.05; Table 2). The stimulation effect was displayed 
in a concentration-dependent fashion, which closely paralleled the relaxation effect of G-
1 (Fig. 9A). Cumulative addition of G-1 relaxed PGF2α-precontracted (1 μM) 
endothelium-denuded porcine coronary artery rings (Fig. 9A and B) and a solvent 
(DSMO) control were performed, and the weakening of the tension with time was not 
significant (Table 3), as we reported previously (235). The maximal relaxation effect of 
G-1 was 45.2 ± 8.9%, with an average EC50 value of 2.67 × 10
−8
 M. These data suggest 
that cAMP contributes to GPER action in porcine coronary artery reactivity. 
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Table 2. G-1 stimulates cAMP production in porcine coronary artery SMCs. Results 
are standardized by control group. Values are given as mean + SE, n=4. **P<0.01, 
***P<0.001, significant difference compared with control by using two-way ANOVA. 
 
 
 
 
 
 
Figure 9. G-1 induces relaxation of precontracted coronary arteries and stimulates 
cAMP production.A: concentration-response relationship for G-1-induced, endothelium-
denuded, prostaglandin F2α (PGF2α)-precontracted (1 μM) coronary artery relaxation. 
Each point represents the mean relaxation effect ± SE. B: cAMP production of the 
porcine coronary artery smooth muscle cells (SMCs) in response to G-1. Cells were 
treated for 30 min in serum and phenol red-free DMEM in the presence of 3-isobutyl-1-
methylxanthine (100 μM) with 0.1% DMSO + G-1 (10–1,000 nM; for each 
treatment, n = 4) and forskolin (F; 1 μM; n = 4). Each point represents the mean 
production ± SE. *P < 0.05, **P< 0.01, ***P < 0.001, and ****P < 0.0001 compared 
with solvent control (C) group. Results are normalized by total protein amount. 
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Table 3. Effects of cAMP/PKA signaling compounds on porcine coronary artery 
relaxation response to 3 μM G-1. Values are given as mean + SE. The number of 
experiments is indicated in parentheses. **P<0.01, ***P<0.001, ****P<0.0001, 
significant difference compared with control by using two-way ANOVA. In the upper 
rows (row 1 to row 5), artery rings were pretreated with each of the inhibitors and the 
results were compared to G-1 alone group (
+
G-1). In the   lower rows (row 6 to row 8),  
++
DMSO group was used as solvent control. 
+++
Forskolin and 6-Bnz-cAMP were used as 
vasorelaxant agents and the results were compared to DMSO group. 
 
3.3.2 The functional role of cAMP 
Next, we tested the functional role of cAMP in GPER-mediated coronary artery 
relaxation. First, the specific adenlylyl cyclase (AC) inhibitor SQ-22536 was used to 
inhibit cAMP production in these artery rings. As shown in Fig. 2A, SQ-22536 (100 μM) 
markedly decreased G-1-induced relaxation, reaching statistical significance at 300 nM 
to 30 μM, increasing EC50 of G-1 from 27 to 277 nM (Table 3). Then the AC activator 
forskolin was used to increase cAMP production in these preparations. As expected, 
forskolin generated a strong concentration-dependent relaxation of endothelium-denuded 
coronary artery rings. The relaxation response to forskolin reached statistical 
significance at concentrations as low as 30 nM, and the EC50 was 101 nM (Table 3 and 
Fig. 10B). The maximal effect of 30 μM forskolin was a 160.3 ± 21.4% reduction in 
precontracted tension, also revealing a significant level of resting tone in these rings. 
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These data suggest that cAMP is a powerful vasorelaxant in porcine coronary artery and 
is involved in the GPER-mediated coronary relaxation. 
 
 
 
 
Figure 10. cAMP is involved in G-1-induced porcine coronary artery relaxation. A: 
concentration-response relationship for G-1-induced relaxation in the presence or 
absence of the adenylyl cyclase inhibitor SQ-22536. Each point represents the mean 
relaxation effect ± SE. *P < 0.05, **P < 0.01, and ***P < 0.001 compared with G-1 
group. B: concentration-response relationship for forskolin-induced porcine coronary 
artery relaxation. Each point represents the mean relaxation effect ± SE. Forskolin-
induced relaxation began at 30 nM and reached the maximal relaxation (160%) at 3 μM. 
 
3.3.3 PKA activity in coronary relaxation 
We then tested the effect of PKA, a direct downstream target protein of cAMP, 
on GPER-mediated relaxation. First, we pretreated the arterial rings with Rp-8-CPT-
cAMPS (5 μM), a membrane-permeant, phosphodiesterase-resistant, and cAMP-
competitive PKA inhibitor. G-1-induced coronary artery relaxation was greatly inhibited 
by Rp-8-CPT-cAMPS (33.4% inhibition; Fig. 11Aand Table 3). To further confirm this 
effect of PKA, we used another PKA inhibitor, the endogenous PKA inhibitor PKI (14–
22) amide (myristoylated). PKI is a small protein that contains a PKA pseudosubstrate  
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sequence. This pseudosubstrate binds to the substrate-binding site of PKA and thus 
prevents substrate binding and hence, is highly specific for PKA. The myristoylation 
increases its membrane permeability. Again, the relaxation effect of G-1 was 
significantly attenuated by inhibiting PKA activity with PKI (14–22) amide (5 μM), the 
G-1 concentration-response curve shifted to the left with EC50 at 278 nM (Fig. 
11B and Table 3). We then used membrane-permeant PKA agonist 6-Bnz-cAMP to 
mimic the effect of G-1 on coronary relaxation. Like G-1, 6-Bnz-cAMP induced a 
concentration-dependent relaxation response. However, the relaxation occurred at a 
much higher concentration (EC50 = 145.3 μM) compared with the parallel G-1 group 
(EC50 = 27 nM) (Fig. 9A and 11C), but it caused an almost complete relaxation (96.3%) 
compared with a maximal G-1-induced relaxation of 44.5% (Table 3). 
To confirm that G-1 indeed stimulates PKA, we measured PKA activity by 
applying the PepTag protein kinase assay in cultured porcine coronary artery SMCs at 
passage 3 (68), taking the advantage of a high concentration of protein extract from 
culture cells. As expected, G-1 (100 nM) raised PKA activity twofold compared with the 
control (Fig. 11D). To test whether the result is receptor specific, G36, an antagonist of 
GPER, was applied (44). G36 (1 μM) completely blocked the effect of G-1 (100 nM) 
and restored PKA activity to the control level (Fig. 11D), suggesting that the increased 
PKA activity is indeed induced by GPER activation. Taken together, with results from 
our tension studies, these findings demonstrate that PKA is involved in GPER-mediated 
coronary relaxation. 
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Figure 11. PKA is involved in the relaxation effect of G-1. A: concentration-response 
relationship for G-1 in the presence or absence of 8-(4-chlorophenylthio)adenosine 3′,5
′-cyclicmonophosphorothioateRp-isomer (Rp-8-CPT-cAMPS; 5 μM), a cAMP analog 
acting as an inhibitor of PKA by competitively binding the cAMP-binding sites. Each 
point represents the mean relaxation effect ± SE. B: concentration-response relationship 
for G-1 in the presence or absence of myristoylated PKI (14–22) (5 μM), the membrane-
permeable version of the specific PKA inhibitor PKI. Each point represents the mean 
relaxation effect ± SE. C: concentration-response relationship for N6-benzoyladenosine-
3 ′ ,5 ′ -cyclic monophosphate (6-Bnz-cAMP)-induced porcine coronary artery 
relaxation. Each point represents the mean relaxation effect ± SE. D: G-1 stimulation of 
PKA activities in porcine coronary artery SMCs measured by the PepTag protein kinase 
assay. DMSO (0.1%) acted as a solvent control, forskolin (1 μM) acted as a positive 
stimulator control, and cells were treated with G-1 (100 nM) in the presence or absence 
of G36 (1 μM), a G protein-coupled estrogen receptor 1 (GPER) antagonist, for 15 min. 
Results are expressed as means ± SE of 3 experiments. *P < 0.05, **P < 0.01, and 
***P < 0.001 compared with the G-1 group. 
 
3.3.4 The state of the phosphorylation of MLC/MLCP 
Vascular tone depends on the phosphorylation state of the smooth muscle MLC.  
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When MLC is phosphorylated, smooth muscle contracts; when it is dephosphorylated, 
relaxation ensues. The responsible phosphatase, MLCP, can be activated by 
dephosphorylation via inhibition of the RhoA/Rho kinase pathway by PKA (6), thus 
dephosphorylating MLC and causing relaxation. To gain additional perspective on the 
mechanisms underlying GPER-induced vasorelaxation, we tested G-1-induced changes 
in the phosphorylation levels of MLC and MLCP and the contribution of PKA to these 
alterations. The regulatory subunit of MLCP, MYPT-1, was examined at the 
Thr
853
position by Western blotting. As expected, PGF2α (1 μM) clearly induced 
phosphorylation of MYPT-1 at Thr
853
, the inactive state of MLCP. The increase of the p-
MYPT-1 at Thr
853
 was significantly attenuated by G-1 treatment (1 μM; Fig. 12A), 
indicating that GPER activation reverses the inhibitory PGF2α-induced phosphorylation 
of MYPT1 at Thr
853
 and thus likely enhances MLCP activity. Moreover, inhibiting PKA 
activity with Rp-8-CPT-cAMPS reduced the effect of G-1 and largely restored the 
phosphorylation of MYPT-1 at Thr
853
 induced by PGF2α, suggesting that the effects of 
G-1 are PKA mediated. 
Because of the low sensitivity of the available MLC antibodies for porcine 
coronary tissue, we were not successful in detecting the MLC protein band in these same 
tissue samples. So we used cultured porcine coronary artery SMCs as an alternative 
approach to enable us to have greater protein extraction and thus better detection of 
MLC protein. These experiments would confirm that inhibition of PKA indeed 
attenuates the effect of G-1 and restores PGF2α-induced inhibition of MLCP activity. 
Passage 3 coronary artery SMCs were treated with PGF2α (1 μM). As expected, this 
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increased p-MLC. G-1 pretreatment reversed the PGF2α-induced density of p-MLC 
levels to control levels. The PKA inhibitor Rp-8-CPT-cAMPS attenuated G-1 effects on 
p-MLC density (Fig. 12B). 
 
 
 
 
Figure 12. G-1 activates myosin light chain phosphatase (MLCP) in porcine coronary 
arteries. A: Western blot detection of myosin-targeting subunit protein-1 (MLCP 
regulatory subunit) phosphorylated at Thr
853
 (p-MYPT-1) in porcine coronary left 
anterior descending (LAD) artery tissue rings. Artery rings were collected from 
isometric tension studies and incubated with DMSO (solvent control), PGF2α (1 μM), 
PGF2α (1 μM) + G-1 (1 μM), and PGF2α (1 μM) + Rp-8-CPT-cAMPS (5 μM) + G-1 (1 
μM). Top: a representative Western blot from 3 individual experiments. Bottom: bar 
graph of the quantitative data of the Western blot bands evaluated by densitometry. 
Protein amounts were normalized to β-actin, which was employed as a control for 
protein loading. B, top: representative p-MLC detection by Western blot from 3 
independent experiments. Porcine coronary artery SMCs (passage 3) were serum-
deprived for 18 h and then treated with drugs, as in porcine coronary tissues. B, bottom: 
bar graph showing the ratio of p-MLC and total β-actin, with the p-MLC and β-actin 
bands evaluated by densitometry. *P < 0.05. 
 
The status of phosphorylation at Thr
853
 of MYPT-1 is in part a manifestation of 
Rho kinase activity (49). Therefore, we measured the activity of its upstream protein 
RhoA in human and porcine coronary artery SMCs by immunoblotting for the 
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Ser
188
 phosphorylation of RhoA (p-RhoA), which leads to inactivation (74), and 
measuring directly the activity of RhoA by G-LISA, a way to measure RhoA activation 
(159). As expected, the immunoblotting results showed in Fig. 13A that G-1 (1 μM) 
treatment of porcine coronary artery SMCs remarkably induced the phosphorylation of 
RhoA to an extent similar to that of forskolin (1 μM) and 6-Bnz-cAMP (10 μM) 
treatments, and pretreatment with PKI (5 μM) completely blocked the response of G-1 
treatment, suggesting that activation of GPER inactivates RhoA activity. Consistently, 
G-LISA RhoA activity measurements in both human and porcine coronary artery SMCs 
confirmed this response of G-1. Cells were incubated with 10% fetal bovine serum to 
induce RhoA activity per the manufacturer's (Cytoskeleton) recommendations. Serum 
increased RhoA activity in both human (~2.5-fold; Fig. 13B) and porcine coronary artery 
SMCs (~3-fold; Fig. 13C). G-1 pretreatment (100 nM, 30 min) significantly inhibited 
both human and porcine coronary artery SMCs RhoA activity by ~50% in both types of 
coronary artery SMCs. The inhibitory effect of G-1 was restored to control (DMSO) 
levels by G36 (1 μM) pretreatment (Fig. 13B and C). Taken together with our 
vasoreactivity data and Western blot analysis, these findings strongly suggest that GPER 
activation mediates coronary artery relaxation through activation of MLCP via inhibition 
of RhoA activity by PKA. 
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Figure 13. G-1 induces phosphorylation of RhoA and attenuates RhoA activities in 
coronary artery SMCs. Human and porcine coronary artery SMCs were serum-deprived 
for 18 h before different drug treatments. A: Western blot detection of phosphorylation 
of RhoA (p-RhoA) at Ser
188
 in porcine coronary artery SMCs (passage 3). Cells were 
treated for 10 min with 0.1% DMSO as solvent control, 6-Bez-cAMP (10 μM), forskolin 
(1 μM), G-1 (1 μM), and PKI (5 μM) + G-1 (1 μM) (n = 3). Top: a representative of p-
RhoA Ser
188
. Bottom: bar graph of the quantitative data of the Western blot bands 
evaluated by densitometry. Protein amounts were normalized to β-actin, which was 
employed as a control for protein loading. B: RhoA activity in human coronary artery 
SMCs (passage 5). Cells were treated for 2.5 min with 0.1% DMSO, 10% serum (S), 
10% S + G-1 (100 nM), and 10% S + G36 (1 μM) + G-1 (100 nM) (n = 3). C: 
RhoAactivity in porcine coronary artery SMCs. Cells were received the same treatment 
as that of human coronary artery SMCs. *P < 0.05 (n = 4). 
 
3.3.5 The role of A-kinase anchoring proteins 
cAMP/PKA signaling is controlled temporally and spatially by A-kinase 
anchoring proteins (AKAPs), which confine PKA activity to relevant subsets of its 
substrates (13, 200). Figure 11D shows that forskolin raises PKA activity levels higher  
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than G-1, indicating that G-1 activates only a subpool of the total cellular PKA. 
Therefore, we tested whether AKAPs play a role by interacting with PKA in GPER-
mediated coronary artery relaxation. In both isometric tension study and Western 
blotting, we applied a small molecule, 3,3′-diamino-4,4′-dihydroxydiphenylmethane 
(FMP-API-1), which inhibits AKAP-PKA interaction and thereby interferes with 
compartmentalized cAMP/PKA signaling (37). In the presence of FMP-API-1 (100 μM), 
G-1-induced relaxation of coronary arteries was significantly inhibited. The maximal 
relaxation was 22.8 ± 9.4%, reaching only about one-half of that in the presence of G-1 
alone (44.51 ± 3.21%; Fig. 14A). In Western blot studies, similarly as described above, 
p-MYPT-1 was stimulated by PGF2α (1 μM) and attenuated by G-1 treatment (1 μM). 
FMP-API-1 treatment clearly reversed the effect of G-1 and restored the p-MYPT-1 
level to a similar extent as treating the tissues with PGF2α alone (Fig. 14B). Together, 
these data suggest that interactions between AKAPs and PKA are involved in the 
cAMP/PKA signaling mediated by GPER in the coronary artery. 
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Figure 14. Inhibition of the interaction between PKA and A-kinase anchoring 
proteins (AKAPs) with the small molecule bis(3-amino-4-hydroxyphenyl)methane 
(FMP-API-1) inhibits G-1-induced relaxation of precontracted porcine coronary 
arteries and activation of MLCP. A: concentration-response relationship for G-1-
induced relaxation in the absence or presence of FMP-API-1 (100 μM). FMP-API-1 
attenuates the relaxation effect of G-1 compared with the G-1 group. B: Western blot 
detection of phosphorylation of MYPT-1 at Thr
853
 in LAD artery tissue rings collected 
from isometric tension studies. Tissue rings were incubated with DMSO (0.1%, as 
solvent control), PGF2α (1 μM), PGF2α (1 μM) + G-1 (1 μM), and PGF2α (1 μM) + 
FMP-API-1 (100 μM) + G-1 (1 μM). Representative Western blot of 3 individual 
experiments. Densitometric analysis of the Western blot experiments normalized to the 
protein loading control β-actin. *P < 0.05; **P < 0.01; ***P < 0.001. 
 
3.4 DISCUSSION 
Convincing evidence has shown that GPER exerts cardiovascular protective 
effects (78, 158, 179). However, knowledge of GPER downstream signaling events in 
the cardiovascular system is lacking. The current study demonstrates for the first time 
that GPER activation increases cAMP production and activates PKA. With the 
involvement of AKAPs, PKA inhibits RhoA activity and thereby activates the MLCP, 
which in turn dephosphorylates MLC and thus causes coronary artery relaxation. 
Although estrogen was first found to enhance cAMP production in human 
coronary arteries 20 years ago (151), the mechanism whereby estrogen elevates cAMP 
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levels has remained undefined. Recently, studies of nonvascular cells have linked GPER 
to increased cAMP production. Filardo et al. (56) reported that when GPER-expressing 
breast cancer cells (i.e., MCF-7 cells with ERα and ERβ present and SKBR3 cells 
devoid of ERα or ERβ expression) were treated with estrogen, AC was stimulated and 
caused cAMP-dependent signaling. On the other hand, estrogen treatment of low-level 
GPER-expressing breast cancer cells (MDA-MB-231 cells expressing ERβ) failed to 
exhibit cAMP production (56). However, transfection of GPER into MDA-MB-231 cells 
greatly increased estrogen-stimulated cAMP production in these cells (56). The increase 
of cAMP attenuated ERK1/2 activity in those breast cancer cells (56). Later, Thomas et 
al. (216) transfected HEK-293 cells with the GPER gene and showed that estrogen 
treatment of the cells resulted in activation of a stimulatory G protein that was coupled 
directly to GPER and increased AC activity. Tamoxifen or ICI-182,780 (anti-estrogens 
now designated as GPER agonists) was found also to increase cAMP production in both 
of these studies (56, 171, 216). The effect of the GPER enhancing cAMP production was 
confirmed in zebrafish oocytes, which are involved in the control of fish oocyte meiotic 
arrest (171). In addition, both G-1 and estrogen greatly increased cAMP content along 
with insulin release in mouse pancreatic islets (8). While this article was in review, 
Lindsey et al. (128) reported that both endothelial release of nitric oxide and cAMP were 
involved in GPER-mediated vasorelaxation in rat mesenteric arteries. However, our 
previous study demonstrated that activation of GPER-induced porcine coronary artery 
relaxation is endothelium independent (235). Apparently, there is heterogeneity in 
GPER-signaling mechanisms among target vessels and cell types (e.g., nitric oxide 
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dependent vs. nitric oxide independent) (78). Our current studies revealed that low 
concentrations of G-1 (e.g., 10 nM) increased cAMP production in coronary smooth 
muscle cells and caused significant coronary artery relaxation. The stimulatory effect of 
G-1 on cAMP production paralleled its ability to relax coronary arteries in a 
concentration-dependent manner. Thus, these experiments are highly indicative of 
cAMP involvement in the vascular relaxation effect of G-1. 
Use of selective cAMP analogs enabled us to test the role of cAMP and its major 
downstream target PKA in isometric tension studies. Our observation that the AC 
inhibitor SQ-22536 significantly inhibited G-1-induced coronary relaxation suggested 
that cAMP mediates GPER-induced relaxation. To verify a role for cAMP in mediating 
coronary relaxation, we applied: 1) the AC activator forskolin to stimulate cellular 
cAMP production without receptor involvement and 2) the cAMP analog 6-Bnz-cAMP 
to activate PKA directly. All concentrations of forskolin and higher concentrations of 6-
Bnz-cAMP caused a much stronger concentration-dependent relaxation than did G-1. 
There are several potential explanations for this difference: 1) forskolin is a more potent 
cAMP activator compared with G-1, as our results showed in Fig. 9, and 2) forskolin has 
additional effects such as inhibiting the activity of ERK1/2 (202). ERK1/2 has been 
reported to cause dephosphorylation of caldesmon and inhibition of actin and myosin 
interaction (46). In addition, 6-Bnz-cAMP has an increased metabolic stability against 
phosphodiesterases compared with cAMP (36). Furthermore, activation of GPER might 
trigger multiple signaling pathways, some of which could counteract cAMP/PKA 
signaling. For example, Filardo and colleagues (53, 56) reported that estrogen activation 
 65 
 
of GPER induced both cAMP production and transactivation of the epidermal growth 
factor (EGF) receptor through the release of pro-heparan-bound EGF from the cell 
surface and increased ERK1/2 activity; however, the increase of cAMP production 
attenuated the ERK1/2 activity a few minutes afterward. 
The importance of PKA in GPER-mediated coronary relaxation was further 
confirmed in our study by applying two highly specific inhibitors: PKI (14-22) 
(myristoylated), a membrane-permeable PKA inhibitor that binds to the catalytic 
subunits of PKA (64, 110); and Rp-8-CPT-cAMPS, a potent competitive inhibitor of 
PKA that functions as a cAMP antagonist with high resistance against mammalian 
phosphodiesterase (36). Consistently, both of these PKA inhibitors exerted significant 
inhibition of G-1-induced coronary artery relaxation. These findings strongly suggest 
that PKA mediates GPER/cAMP downstream signaling. However, we cannot 
completely dismiss the possibility of the contribution from the alternative cAMP target 
Epac (exchange protein directly activated by cAMP), which functions as guanine 
nucleotide exchange factors for the small G protein Rap and plays a role in cardiac 
contraction and vascular permeability (65). It is possible that both PKA and Epac are 
involved in the signaling mediated by GPER in coronary artery relaxation. Currently, the 
role of the Epac/Rap signaling in GPER-mediated coronary relaxation is under 
investigation in our laboratory. 
Some evidence suggests that ion channels are involved in PKA-mediated 
vascular smooth muscle relaxation through decreasing intracellular Ca
2+
 levels. 
Urocortin-induced, endothelium-independent rat coronary artery relaxation was shown 
 66 
 
to be mediated primarily through PKA-dependent BKCa channels opening (93). Under 
normoxic conditions, forskolin or a selective PKA agonist opened BKCa channels in 
pulmonary artery smooth muscle cells, and these effects could be attenuated by hypoxia 
(9). In rat aortic smooth muscle, however, all potassium channels were reported to be 
responsible for about 80% relaxation induced by the ERβ activator diarylpropionitrile 
(ERβ selective ligand) and mediated by PKA (219). In rat mesenteric artery, vasoactive 
intestinal polypeptide caused relaxation through PKA-stimulated KATP channels (233). 
Store-operated Ca
2+
 entry was also demonstrated to be involved in coronary artery 
relaxation mediated by a PKA-dependent mechanism under urocortin treatment (201). 
Thus, it seems that ion channels, especially BKCa channels, play an important role in 
PKA-mediated vascular smooth muscle relaxation by lowering intracellular Ca
2+
. Our 
previous work demonstrated that BKCa channels are involved in G-1-induced porcine 
coronary artery relaxation. Therefore, we speculate that BKCa channels might be 
involved in the PKA-dependent mechanism of G-1-induced coronary artery relaxation. 
However, future study is needed to validate this speculation. 
Studies also have demonstrated that cAMP/PKA signaling may inactivate RhoA 
by phosphorylating RhoA at Ser
188
, thereby releasing the inhibitory effect of RhoA and 
Rho kinase on MLCP, and therefore allow MLCP to dephosphorylate MLC and relax 
vascular smooth muscle independent of intracellular Ca
2+
 level (74, 182). MLCP activity 
depends largely upon the phosphorylation status of its regulatory subunit MYPT-1 at 
Thr
696
 and Thr
853
. When one or two of these sites is/are dephosphorylated, MLCP will be 
activated to dephosphorylate MLC and induce relaxation (106). The increased Rho 
 67 
 
kinase activity by various vasoconstrictors elevates phosphorylation of MYPT-1 at 
Thr
853
 but not at Thr
696
 (49, 109). Although phosphorylation of MYPT-1 at Thr
696
 is 
insensitive to stimuli by most agonists, it is often spontaneously phosphorylated under 
resting conditions (106, 109). Therefore, we only studied the phosphorylation of MYPT-
1 at Thr
853
. Our results showed that G-1 treatment induced phosphorylation of RhoA at 
Ser
188
 to a similar extent as that of forskolin and 6-Bnz-cAMP, attenuated serum-induced 
RhoA activity in human and porcine coronary smooth muscle cells, and inhibited 
PGF2α-induced phosphorylation of MYPT-1 at Thr853 in porcine coronary artery and 
that the PKA inhibitor Rp-8-CPT-cAMPS reversed the inhibition effect of G-1. 
Similarly, in porcine coronary artery SMCs, G-1 treatment decreased phosphorylation of 
MLC, which was reversed by Rp-8-CPT-cAMPS. These results indicate that 
cAMP/PKA is involved in the response to G-1, and the result that G-1 increased PKA 
activity in porcine coronary artery SMCs further confirmed this notion. Consistent with 
our results, it was reported previously that forskolin and db-cAMP, a PKA activator, 
inhibited a KCl-induced increase in MYPT-1 phosphorylation at Thr
853
 and the 
phosphorylation of MLC, thus relaxing femoral arteries from adult New Zealand white 
rabbits (176). Taken together, these findings suggest that through cAMP/PKA signaling, 
G-1 induced activation of MLCP, which resulted in dephosphorylation of MLC in 
coronary artery SMCs. 
cAMP/PKA signaling is compartmentalized and functions locally by anchoring 
to the AKAPs (13, 200). Consistent with this notion, a recent study indicated that the 
classic estrogen receptors ERα and ERβ are colocalized with AC in the caveolae of 
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vascular SMCs from rat mesenteric arteries and that estrogen increases cAMP 
production locally, not globally, in these cells (104). AKAPs are signaling scaffolds that 
contribute to cAMP signaling in various aspects. They can bind to AC to regulate cAMP 
synthesis and sequester phosphodiesterases to break down this second messenger locally. 
In addition, they tether PKA to specific subcellular sites, thereby focusing the activity of 
PKA toward relevant substrates (13, 166). In vascular SMCs, studies have shown that 
the AKAP complex regulates specific vascular SMC functions, such as inhibition of cell 
migration, by causing localized changes in actin dynamics and reduction in cell 
proliferation and neointimal hyperplasia by stimulating cAMP-induced transcription and 
increasing the levels of the cyclin-dependent kinase-2 inhibitor p27kip1 (96, 186). In 
addition, the localization of PKA through binding to AKAPs facilitates stimulation of L-
type Ca
2+
 channels in rabbit portal vein SMCs by endogenous PKA (239). Our novel 
findings from the current studies reveal that the localization of PKA by binding to 
AKAPs relaxed coronary smooth muscle through the inhibition of RhoA/Rho kinase 
(ROCK) signaling. We showed that the small molecule inhibitor of AKAP-PKA 
interactions, FMP-API-1 (37), significantly inhibited G-1-induced coronary relaxation. 
Furthermore, FMP-API-1 blocked the inhibitory effect of G-1 on the phosphorylation of 
MYPT-1 at Thr
853
, which is the target site of ROCK. These results suggest that the 
binding of PKA to AKAPs is required for GPER-mediated coronary artery relaxation. 
The relevant isoforms and their localization remain unknown. Their identification is 
beyond the scope of this study. Candidates involved in controlling relaxation are the 
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three AKAPs reportedly expressed in vascular SMCs: AKAP75 (a membrane AKAP) 
(80), AKAP5, and gravin (AKAP12) (186). 
In conclusion, we have shown for the first time that GPER-mediated porcine 
coronary relaxation involves localized cAMP/PKA signaling to release the RhoA/ROCK 
inhibitory effect on MLCP, resulting in decreased phosphorylation of MLC (Fig. 15). 
This has implications for GPER regulation of vascular tone in health and disease. Our 
findings now provide a molecular basis for developing new compounds that better target 
estrogen signaling for a variety of clinical applications. 
 
 
 
 
Figure 15. Proposed mechanism of GPER-mediated porcine coronary artery 
relaxation signaling. When GPER is activated by agonist G-1, it activates the G protein 
Gs, which in turn stimulates adenlylyl cyclase (AC), thus increasing cAMP production 
and activation of its effector PKA; PKA phosphorylates RhoA at Ser
188
, thereby 
inhibiting RhoA and its effector Rho kinase (ROCK). This activates myosin light chain 
phosphate (MLCP) by increasing dephosphorylated MYPT-1, leading to 
dephosphorylation of MLC20 and relaxation. 
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CHAPTER IV 
ACTIVATION OF G PROTEIN-COUPLED ESTROGEN 
RECEPTOR 1 INDUCES CORONARY ARTERY RELAXATION 
VIA EPAC/RAP1-MEDIATED INHIBITION OF RHOA/RHO 
KINASE PATHWAY IN PARALLEL WITH PKA 
 
4.1 INTRODUCTION 
Cardiovascular disease (CVD) has become the leading cause of death in the 
world, overtaking infectious diseases as the first cause of death in developing countries 
and joining industrial countries (29). Compared to men, childbearing women have lower 
incidence of CVD and that was credited to estrogen. Epidemiological studies have 
shown that the onset of CVD in pre-menopausal women occurs approximately 10 years 
later than that in men and myocardial infarction occurs 20 years later. However, after 
menopause, the risk of coronary heart disease increase was 10-fold, compared to only a 
4.6 fold increase in the same age groups in men (50). Again the decrease in estrogen of 
menopausal women has been considered a major contribution to this increase. Evidence 
from earlier observational studies favored the concept that menopausal hormone 
treatment (MHT) protects against CVD. However, the Women's Health Initiative (WHI) 
MHT trials failed to demonstrate the estrogen’s CVD benefit, with increased CVD 
incidences for menopausal hormone treatment versus placebo (92, 134). Taking the age 
factor into consideration, data from WHI suggests that younger/recently menopausal 
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women may have a better risk-benefit ratio than older/remotely menopausal women. In 
this regard, WHI women averaged 63 years of age, approximately12 years 
postmenopausal (81). Nevertheless, older menopausal women are at the highest risk of 
CVD and there is no “ideal” treatment available for this population yet.  
A highly novel and promising therapeutic target for treating cardiovascular 
disease is the recently-identified membrane-associated, G-protein-coupled estrogen 
receptor 1 or GPER (78). GPER activation reduces blood pressure, heart and brain 
infarct extent (45, 238), and relaxes peripheral blood vessels (75, 127). Moreover, 
selective activation of GPER relaxes porcine coronary arteries (79, 144, 236). The 
mechanism of GPER-mediated vascular relaxation is, however, far from clear. As a 
typical G-protein-coupled receptor, GPER has been reported coupling to Gs, activates 
adenylyl cyclase, and increasec AMP production in GPER transfected HEK293 cells and 
human coronary artery SMCs (53, 234). Our recent work has demonstrated that 
cAMP/PKA signaling is involved in GPER-mediated relaxation. In human and porcine 
coronary artery SMCs, GPER activation increased cAMP production and activated PKA 
activity which in turn phosphorylated RhoA, thus, inhibited RhoA activity, resulting in 
activation of the myosin light chain (MLC) phosphatase (MLCP) and dephosphorylation 
of MLC (234). 
The newly-discovered target of cAMP, Epac, exchange proteins directly 
activated by cAMP,  is known to be a novel downstream mechanism for cAMP to 
govern signaling in the cardiovascular system and other tissues (141, 189), and its 
primary function is to act as a guanine nucleotide exchange factors (GEF) for Rap 
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GTPases -- which act as molecular switches that cycle between an active GTP-bound 
state and an inactive GDP-bound state (41). It has been reported that Epac agonist 
induced pulmonary and portal vein relaxation by activation of MLCP via Rap1 
inhibition of Rho Kinase activities (241). In this study, we explored the role of Epac and 
its downstream signaling in mediating GPER-induced coronary relaxation. 
 
4.2 MATERIAL AND METHODS 
4.2.1 Tension studies 
Fresh porcine hearts were obtained from local abattoir, K&C Meat Processing, 
immediately placed in cold Dulbecco’s Phosphate Buffered Saline (Sigma) and 
transported back to the laboratory. Left anterior descending (LAD) coronary arteries 
were dissected from the fat and connective tissue, and cut into rings (axial length ~ 5 
mm) to be used in isometric contractile force recordings. Arteries were endothelium-
denuded to eliminate effects of endothelium-derived vasoactive factors. Only the rings 
with successful endothelium denudation were used, which was confirmed by the absence 
of relaxation to bradykinin (100 nM) exposure. Arterial rings were mounted on the two 
wires of isometric myographs (Danish Myograph Technology)filled with 10-ml 
modified Krebs-Henseleit buffer (in mM): 122 NaCl, 4.7 KCl, 15.5 NaHCO
3
, 1.2 
KH
2
PO
4
, 1.2 MgCl
2
, 1.8 CaCl
2
, 11.5 glucose, pH 7.2, bubbled with 95% O2–5% CO2 
(pH 7.4) at 37 °C. One wire was connected to a force-displacement transducer and the 
other to a stationary micrometer. The equilibrate time for the preparations in Krebs-
Henseleit buffer was 90 min. The optimal resting tension was set at 20mN in the first 30 
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min by gradually stretching the artery rings as in our previous work (234, 235). 
Isometric tension was recorded by using the LabChart data acquisition system (AD 
Instruments) on a PC computer.  The preparations were contracted, washed and allowed 
to relax to basal tension for 3 times with PGF2α (1 µM). Then PGF2α (1 μM) was used 
to induce a stable contraction and G-1 was added in a cumulative manner by increasing 
the concentration in log increments. Pharmacological inhibitors were applied 30 min 
prior to measurement of a complete G-1or other vasodilators effects. In each set of 
experiments, one ring was exposed only to the constrictor agent PGF2α (1 μM) and 
vehicle as time control for potential fading of the contractile response.  The vehicle 
(dimethylsulfoxide, DMSO) was added in cumulative manner by adding the identical 
amount of DMSO used for each concentration of G-1, 8-(4-chlorophenylthio)-2-O-
methyladenosine-3,5-cyclicmonophosphate, 8-CPT-2Me-cAMPS (007). The total 
amount of vehicle was less than 0.1%. Relaxation responses were calculated as the % 
reduction in tension at each G-1 concentration from the precontracted state.  
4.2.2 Vascular smooth muscle cell culture 
Human coronary artery smooth muscle cells (SMCs) were purchased from Life 
Technologies Corp and maintained in SmGM at 37ºC in a humidified 5% CO2 incubator. 
The primary porcine coronary artery SMCs culture was established as described 
previously (226, 227). Coronary arteries were isolated from porcine hearts. After 
removing the endothelial layer with a cotton-tipped swab, the media layer was dissected 
free from the adventitia. The medial layer was then cut into small pieces and then moved 
into a 25-cm
2
 tissue culture flask containing 10 ml dissociation medium (in mM): 110 
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NaCl, 5 KCl, 2 MgCl2, 0.16 CaCl2, 10 HEPES, 10 NaHCO3, 0.5 KH2PO4, 0.5 NaH2PO4, 
0.48 EDTA, 10 taurine, and 10 glucose, in addition of 24 mg elastase, 6 mg collagenase, 
and 15% bovine serum albumin. After gently shaking at 37
o
C for 3 hours, cells were 
then dispersed by gentle trituration and centrifuged at 800 rpm for 5 min. The pellet was 
resuspended with coronary artery SMC medium, SmGM (Lonza Corp.) and cells were 
seeded in a 25-cm
2
 tissue culture flask coated with 1% gelatin.  The purity of porcine 
coronary artery SMCs was verified by positive staining with smooth muscle-specific α-
actin (120). Passage 3 and 4 of porcine and passage 5 of human coronary artery SMCs 
were used in this study. 
4.2.3 Western blot 
Phosphorylation of MYPT-1 (pMYPT-1), the regulatory subunit of MLCP, from 
porcine coronary artery tissue lysates, phosphorylation of MLC (p-MLC) and 
phosphorylation of vasodilator-stimulated phosphoprotein (pVASP) and p-RhoA from 
porcine coronary artery SMC lysates were detected with Western blot analysis as 
previously described (234). Briefly, arterial rings were prepared as in isometric tension 
studies and mounted in the chamber of the myograph, equilibrated, and contracted three 
times with PGF2α(1 μM) as described above.  Artery rings were pretreated with agonist 
with or without antagonists for 30 min before exposed to PGF2α (1 μM). Then the ring 
tissues were collected at the point of reaching contraction plateau and were snap frozen 
in liquid nitrogen. Tissues were pulverized (Fisher Scientific) and lysed in 
homogenization buffer, the composition of the buffer is (mM): 50 Tris–HCl, 0.1 EGTA 
and 0.1 EDTA, with 0.1% SDS, 1% NP-40, and 0.1% deoxycholic acid. For MLC20 and 
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VASP phosphorylation detection, porcine coronary artery SMCs were treated with 
agonists and antagonists as indicated in the results. Then the cells were harvested and 
homogenized. Protein concentrations were determined by using Detergent-compatible 
colorimetric assay kit (Bio-Rad). Proteins were separated by using a Mini Protean II 
SDS-PAGE gel kit (Bio-Rad) according to the manufacturer’s instructions.  
After separation, proteins were transferred to Hybond enhanced 
chemiluminescence (ECL) membrane (Amersham Pharmacia Biotech) with a Mini-
Trans-Blot Electrophoretic Transfer Cell (Bio-Rad) at constant voltage of 100 for 1 hour.  
Then membranes were blocked with 5% fat free milk for 1 hour at room temperature and 
rinsed with Tris-buffered saline (TBS)-Tween (TBST) three times, each time is 5 
minutes. Membranes were then probed with specific primary antibodies in TBST 
containing 5% fat free milk overnight at 4°C (dilution p-MYPT-1, Thr
853
 p-MYPT-1, 
1:1000, Santa Cruz Biotechnology ; p-MLC , Ser
19
,1:1000, Cell Signaling;  p-VASP, 
Ser
157
, 1:1000,Cell Signaling; p-RhoA, Ser
188
, 1:200, Santa Cruz Biotechnology). The β-
actin primary antibody (dilution: 1:2000, Santa Cruz Biotechnology) was used for 
protein loading control in the protein band densitometry analysis. Experiments were 
performed at least in triplicate, and mean values ± SE were calculated and made graph. 
4.2.4 Rap 1 activation assay 
The Rap1 activation assay is based on the differential affinity of Rap1-GTP and 
Rap1-GDP for the Rap binding domain of Ral GDS as described in the manufacturer’s 
protocol. Rap1 activity was determined by using a Rap1 activation kit (Upstate 
Biotechnology). Briefly, porcine coronary artery SMCs were treated with G-1 (1 µM) 
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between 2 and 15 min with or without Farnesyl Thiosalicylic Acid (FTS, 100 µM), a 
potential Rap1 inhibitor (149) and 007 (50 µM) for 5 min. Cell lysates were incubated 
with glutathione agarose beads pre-coupled to GTPγS. Following the 45mins incubation 
at 4°C, beads were rinsed three times with ice-cold lysis buffer and proteins were eluted 
from the beads in Laemmli reducing sample buffer and were probed with anti-Rap1 
polyclonal antibody by Western blot as described above. 
4.2.5 RhoA activation assay 
Porcine coronary artery SMCs, passage 2-3, were serum- deprived 24 hour  when 
cells reached approximately 50% confluence. After incubated with 0.1 % DMSO (as 
solvent control), PGF2α (1 µM), PGF2α (1 µM) +G-1 (1 µM), and PGF2α (1 µM) +G36 
(5 µM) + G-1(1 µM), cells were harvested, centrifuged at 4°C and10 kg for 2 min and 
the supernatant was discarded. Active Rho A- GTP activity was measured by using with 
RhoA G-LISA kit (Cytoskeleton), a direct measurement of RhoA activity (159), 
according to the manufacturer’s instructions. Briefly, Cell lysates were equalized 
according to the total amount of the proteins and loaded into a Rho-GTP binding 96 well 
plate, incubated with Anti-RhoA antibody and then secondary antibody. Absorbance was 
read at 490 nm. Active RhoA was normalized against total RhoA in comparison of 
RhoA activity between groups.  
4.2.6 Statistical analysis 
In tension studies, comparisons were made between the presence and the 
absences of selective antagonist or the solvent control and vasorelaxants. Different 
treatments with accumulative concentrations were analyzed by using two-way analysis 
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of variance (ANOVA).  Data was presented as mean percentage relaxations, with the 
standard error of the mean (SE) and the number of experiments was indicated in 
parentheses. Statistical differences were analyzed with Prism program (GraphPad 
Software Inc., San Diego, CA). In immunoblotting detection, one way ANOVA was 
used to detect significant differences among all treatments and student’s t-testis used in 
paired groups. Bonferroni correction was used to correct type 1 error associated with 
multiple comparisons. A P value ≤0.05indicated a significant difference. 
4.2.7 Drugs 
G-1 was purchased from Calbiochem, 8-(4-chlorophenylthio)-2-O-
methyladenosine-3,5-cyclicmonophosphate [8-CPT-2Me-cAMPS (007)]and 3- [5- (tert.-
 Butyl)isoxazol- 3- yl]- 2- [2- (3- chlorophenyl)hydrazono]- 3- oxopropanenitrile ( ESI-
09)arefrom Biolog Life Science Institute. PKI (14-22) amide (myristoylated) is from 
Enzo Life Sciences. Brefeldin A is from LC laboratories. Farnesyl Thiosalicylic Acid is 
from Cayman Chemical. All other chemicals were purchased from Sigma-Aldrich 
Corporation. 
 
4.3 RESULTS 
4.3.1 Epac and coronary artery relaxation 
The pretreatment of artery rings with ARF-GEF inhibitor brefeldin A (BFA, 50 
μM), a proven Epac inhibitor (241), significantly attenuated G-1-induced porcine 
coronary artery relaxation, the reduced relaxation was 44.90% of the total relaxation 
effect of G-1 (Fig. 16A, Table 4), similar to the effect of PKI (14-22) amide (5 µM), a 
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PKA inhibitor, in our previously study (234). When artery rings were pretreated with 
both BFA (50 μM) and PKI (5 µM), the inhibition of G-1-induced relaxation response 
reached to 76.98% (Fig. 16B, Table 4), suggesting an additive effect of Epac and 
PKA.As expected, the 8-CPT-2Me-cAMPS (007), an analogue highly selective for 
activation of Epac (190), caused a concentration-depend response of coronary artery 
relaxation (Fig. 16C, Table 4). However, the significant relaxation occurred at much 
higher concentration (EC50 = 49.4 µM), compared to G-1 (EC50 =0.027 µM), but it was 
similar to the effect of PKA agonist 6-Bnz-cAMP in our previous study (234). 
 
 
 
 
Figure 16. Epac is involved in the G-1-induced relaxation of precontracted coronary 
arteries. A & B: Concentration-response relationship for G-1-induced endothelium 
denuded, PGF2α (1 µM) precontracted, coronary artery relaxation, in the presence or 
absence of the Epac inhibitor, BFA (A); in the presence or absence of both Epac and 
PKA inhibitor, BFA and PKI (B). Each point represents the mean relaxation effect ± SE, 
*** p<0.001, compared to G-1 group. C: Concentration-response relationship for Epac 
agonist 8-CPT-2Me-cAMP (007)-induced porcine coronary artery relaxation. Each point 
represents the mean relaxation effect ± SE, *** p<0.001, **** p<0.0001, compared to 
the solvent control group. 
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Table 4. Effects of Epac signaling compounds on porcine coronary artery relaxation 
response to 3 μM G-1. Values are given as mean ± SE. The number of experiments is 
indicated in parentheses. ***P<0.001, ****P<0.0001, significant difference compared 
with control by using two-way ANOVA. In the upper rows (row 1 to row 4), artery rings 
were pretreated with each of the inhibitors and the results were compared to G-1 alone 
group (
+
G-1). In the   lower rows (row 5 to row 6), 
++
DMSO group was used as solvent 
control. 
+++
8CPT-2Me-cAMP was used as vasorelaxant agents and the results were 
compared to DMSO group. 
 
4.3.2 Rap1 and VASP 
Pre-exposure artery rings with the potential Rap1 inhibitor, Farnesyl 
Thiosalicylic Acid (FTS, 100 µM) (149), significantly inhibited the relaxation effect of 
G-1, indicating that Rap1 is functionally involved in GPER-mediated relaxation (Fig. 
17A). Then we measured the Rap1 activity in the porcine coronary artery SMCs (Fig. 
17B). G-1 (1 µM) treatment of the cells increased Rap1 activity at 2.5 min and 5 min, to 
the similar extend as the 007 (50 µM). Furthermore, the increased Rap1 activity induced 
by G-1 (1 µM) was completely blocked by BFA (50 µM). Together, these results 
suggest that as a downstream of Epac, Rap1 is involved in GPER-mediated coronary 
artery relaxation.  
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Figure 17. Rap1 is involved in G-1-induced porcine coronary arteries relaxation. A: 
Concentration-response relationship for G-1-induced relaxation in the presence or 
absence of the potential Rap1 inhibitor Farnesyl Thiosalicylic Acid (FTS). Each point 
represents the mean relaxation effect ± SE, * p<0.05, ** p<0.01, **** p<0.0001, 
compared to G-1 group. B: Rap1 activity measured by using a Rap1 activation kit 
(Upstate Biotechnology). Porcine coronary artery SMCs (passage 4 and 5) were serum 
deprived for 24 hour, then treated with: BFA (50 µM) + G-1 (1 µM); G-1 (1 µM) for 0, 
2.5, 5, and 15 min; 007 (100 µM). Upper panel is a representative Western blot of Rap1-
GTP and Rap1-GDP from 3 individual essays.  Rap1-GTP is the active form of Rap1 
and Rap1-GDP is the inactive form of Rap1. The lower panel is a summary bar graph of 
the Rap1 Western blot bands analyzed by densitometry. Rap-GTP/Rap1-GDP ratio was 
normalized to control % (0 min of G-1 treatment) according to the manufacture 
instruction.  * p<0.05, compared to control. 
 
The phosphorylation of Vasodilator-stimulated phosphor protein (VASP) can be 
phosphorylated by PKA at Ser157, thus reflecting PKA activity (241).  As expected, in 
porcine coronary artery SMCs, G-1 increased p-VASP, 007 did not, and the increase of 
p-VASP induced by G-1 was totally blocked by PKI while the antagonist of Epac, ESI-
09, had no effect (Fig. 18), suggesting that Epac and PKA are two separated downstream 
targets of GPER and there is no cross talk between these two at the phosphorylation of 
VASP.    
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Figure 18. G-1 increases phosphorylation of VASP. Porcine coronary artery SMCs 
(passage 4and 5) were serum deprived for 24 hour and then treated with: 0.01% DMSO 
as solvent control; 007 (50 µM); G-1 (1 µM); G-1(1 µM) + ESI-09 (10 µM) and PKI (5 
µM). Upper panel is a representative of Western blot for p-VASP and β–actin of 3 
individual experiments. Lower panel is a summary bar graph of the Western blot band 
densitometry analysis. Results are expressed as mean ± SE, * p<0.05, compared to the 
solvent control. 
 
4.3.3 RhoA activity 
Previously we have shown that PKA was involved in G-1 inhibition of RhoA 
activity (234). Now we measured the activity of RhoA and the inactivation state of 
RhoA (74), the phosphorylation of RhoA at Ser
188
 (p-RhoA), by treating porcine 
coronary artery SMCs with 007 andESI-09 to test whether Epac plays a role in GPER-
mediated inhibition of RhoA activity.  The results showed that 007 (50 µM) inhibited 
RhoA activity to the similar extend as G-1 (1 µM) and ESI-09 (10 µM) significantly 
inhibited the effect of G-1 (Fig. 19A). Furthermore, the immunoblotting results showed 
that both 007 (50 µM) and the PKA agonist 6-Benz-cAMP (50 µM) increased p-RhoA 
similarly as that of G-1 (1 µM).  The G-1 effect of increasing p-RhoA was significantly 
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inhibited by either PKI or ESI-09 (Fig. 19B). Together, these results suggest that GPER 
activation inhibits RhoA activity through phosphorylation of RhoA via both Epac and 
PKA signaling.  
 
 
 
 
Figure 19. Epac is involved in the G-1-induced phosphorylation of RhoA and the 
inhibition of RhoA activities in coronary artery SMCs. Porcine coronary artery SMCs 
were serum deprived for 18 hour before being treated with different drugs.  A: RhoA 
activity in porcine coronary artery SMCs (passage 4 and 5). Cells were treated for 2.5 
min with 0.1% DMSO, 10% serum, serum + 007 (100 µM), 10% serum + G-1 (100 nM), 
10% serum + ESI-09 (10 µM) + G-1 (100 nM) (n=3), * p<0.05, compared to groups as 
indicated. B:  Western blot detection of phosphorylation of RhoA at Ser
188
 in porcine 
coronary artery SMCs (passage 4 and 5). Cells were treated for 10 minutes with: 0.1% 
DMSO as solvent control; 007 (100 µM); 6-Bnz-cAMP (10 µM); G-1 (1 µM); ESI-09 
(10 µM) + G-1 (1 µM) and PKI (5 µM) + G-1 (1 µM) (n=3). Upper panel: a 
representative Western blot phosphor-Ser
188 RhoA and β-actin of 3 experiments.  Lower 
panel: Bar graph of the quantitative data of the p-RhoA bands evaluated by 
densitometry. Sample protein amounts were normalized to β-actin which was employed 
as a control for protein loading, * p<0.05, compared to the groups as indicated. 
 
4.3.4 Phosphorylation of MLCP/MLC 
Increased RhoA activity leads to phosphorylation of MYPT1 at Thr
853
 via Rho 
kinase (49, 109). In Western blotting study, G-1 (1 µM) inhibited phosphorylation of 
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MYPT1 at Thr
853
 induced and phosphorylation of MLC by PGF2α (1 µM) either in 
coronary artery rings or porcine coronary artery SMCs (Fig. 20); and the inhibition 
effect of G-1 was partially restored either by ESI-09 (10 µM) or by FTS (100 µM). 007 
(50 µM) exerted similar inhibition effect on the phosphorylation of MYPT1 at Thr
853
 
and MLC as that of G-1 (1 µM), suggesting that Epac/Rap1 signaling is involved in the 
GPER-mediated inhibition of p-MYPT-1 and p-MLC. In another set of experiments, 
both Epac and PKA antagonists were used in examining the role of Epac as well as PKA 
in the inhibition effect of G-1 on the phosphorylation of MYPT1 and MLC. When added 
separately, ESI-09 (10 µM) as well as PKI (5 µM) exerted partial restoration effect on 
the inhibition of phosphorylation of MYPT1 and MLC mediated by G-1; however, when 
both of ESI-09 (10 µM) and PKI (5 µM) were present, the G-1 induced inhibition of the 
phosphorylation of MYPT1 and MLC was completely restored (Fig. 21). These results 
suggest that Epac/Rap1 signaling along with PKA is involved in the GPER-mediated 
inhibition of the phosphorylation of MLCP/MLC. 
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Figure 20. Epac and Rap1 are involved in the G-1 activation of MLCP in porcine 
coronary arteries. A: Western blot detection of phosphorylation of MLCP at the 
regulatory subunit, myosin-targeting subunit protein-1 (pMYPT-1 at Thr
853
) in porcine 
coronary artery tissue rings. Artery rings in isometric tension studies were incubated 
with DMSO (solvent control, 0.1 %); PGF2α (1 µM); PGF2α (1 µM) + G-1 (1 µM); 
PGF2α (1 µM) + ESI-09 (10 µM) +G-1 (1 µM); PGF2α (1 µM) + FTS (100 µM) +G-1 
(1 µM); and PGF2α (1 µM) + 007 (100 µM). Upper panel: A representative Western blot 
for p-MYPT1 from three individual experiments. Lower panel: Bar graph of the 
quantitative data of the Western blot bands evaluated by densitometry. Tissue sample 
protein amounts were normalized to β-actin which was employed as a control for protein 
loading, * p<0.05, compared between groups as indicated. B: Upper panel: the 
representative p-MLC detection by Western blot from three independent experiments. 
Porcine coronary artery SMCs (passage 4) were serum deprived for 24 hours, and then 
treated with drugs as in porcine coronary tissues, except that the concentration of ESI-09 
was 10 µM. Lower panel: Bar graph showing the summary data of p-MLC which was 
normalized to total β-actin, the bands were evaluated by densitometry, * p<0.05, 
compared to the group as indicated. 
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Figure 21. Epac and PKA exert additive effect on G-1-induced activation of MLCP in 
porcine coronary arteries. A: Western blot detection of pMYPT-1 at Thr
853
 in porcine 
coronary artery tissue rings. Artery rings were treated with: DMSO (solvent control, 0.1 
%); PGF2α (1 µM); PGF2α (1 µM) + G-1 (1 µM); PGF2α (1 µM) + ESI-09 (10 µM) 
+G-1 (1 µM); PGF2α (1 µM) + PKI (5 µM) + G-1 (1 µM); and PGF2α (1 µM) + ESI-09 
(10 µM) + PKI (5 µM) + G-1 (1 µM). Upper panel: A representative Western blot for p-
MYPT1 from three individual experiments. Lower panel: Bar graph summary of the 
quantitative data of the Western blot p-MYPT-1 bands evaluated by densitometry. 
Tissue sample protein amounts were normalized to β-actin. * p<0.05, compared between 
groups as indicated in the graph. B: Upper panel: A representative p-MLC detection by 
Western blots of three independent experiments. Porcine coronary artery SMCs (passage 
4) were serum deprived for 24 hours, and then incubated with the drugs as used in 
porcine coronary tissues, except that 10 µM of ESI-09 was used rather than 25 µM. 
Lower panel: Bar graph showing the summary data of p-MLC normalized to total β-
actin, the bands were evaluated by densitometry, * p<0.05, compared to the group as 
indicated in the graph. 
 
4.4 DISCUSSION 
There is a growing interest in the role of GPER in cardiovascular regulation. This 
work is the first to define the cAMP/ Epac signaling pathway in GPER-mediated 
coronary artery relaxation, which is through attenuation of phosphorylation of MLCP 
and MLC via Rap1 inhibition of RhoA activity in parallel with PKA.  
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 GPER activation induces vascular dilation in a variety of vascular beds (75, 127, 
145, 235) and reduces tissue damages after heart ischemia-reperfusion or stroke (45, 
238). However, our understanding of the mechanism of GPER-mediated vasorelaxation 
has just begun. Our recent work has shown that: G-1 treatment of porcine coronary 
artery SMCs activated adenylyl cyclase (AC) and increased cAMP production in a 
concentration-dependent manner; isometric tension study showed that blocking of AC 
inhibited G-1 induced porcine coronary artery relaxation, suggesting cAMP was 
involved in the GPER-mediated coronary artery relaxation. The downstream PKA 
signaling was then proven playing a role in GPER-mediated coronary vasorelaxation by 
activating MLCP via inhibition of RhoA pathway (234). Now we have found that, along 
with PKA, Epac/Rap1 signaling is also involved in the GPER-mediated vasorelaxation 
via inhibition of RhoA pathway.   
The elevation in intracellular concentration of cAMP after Gs-protein-coupled 
receptors activation is sufficient to activate EPAC (189). Now Epac is recognized as a 
novel mechanism in the regulation of cardiovascular functions (141).  Two isoforms of 
Epac, Epac1 and Epac2, have been identified (141). Epac1 is the predominant isoform 
found in VSM of rat aorta and mesenteric artery (183). Activation of Epac1could induce 
relaxation of adrenaline-contracted rat aortae (210) and phenylephrine-contracted rat 
mesenteric arteries (241). In the present study, G-1 induced porcine coronary artery 
relaxation can be significantly attenuated with ARF-GEF inhibitor brefeldin A (50 μM), 
which was shown to be an Epac inhibitor (241); furthermore, the Epac specific agonist 
8CPT-2Me-cAMP (007) mimicked the relaxation effect of G-1. Together these findings 
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suggest that Epac, as a cAMP downstream, is also involved in the GPER-mediated 
relaxation effect; and functioned similarly as PKA mediating GPER vasorelaxation 
effect as reported in our previous study (234).   
Epac is the best described guanine nucleotide exchange factor (GEF) in 
cardiovascular system, and facilitates Rap1 cycling from the (GDP-bound) inactive state 
to the (GTP- bound) active state (99).Rap1 as members of the Ras family are involved in 
the network of multiple proteins to regulate vascular endothelial cell proliferation, 
migration and endothelial permeability as well as vascular tone (38). Rap1b in both 
smooth muscle and endothelium plays a key role in maintaining blood pressure. 
Rap1b−/− mice developed basal tone elevation and hypertension that was probably 
caused by: 1) increased contractility of smooth muscle to contractile agents, such as, 
thromboxane, angiotensin II or phenylephrine; 2) defective endothelial release of 
dilatory nitric oxide in response to elevated blood flow (116). We tested the effect of 
GPER activation on Rap1 in porcine coronary artery SMCs and observed that G-1 (1 
µM) markedly increased Rap1 activity between 2 and 5 minutes, to the similar extend as 
007, and the increase was blocked by BFA (50 μM), suggesting that GPER activation 
stimulates Rap1 activity via Epac in coronary artery SMCs. The isometric tension study 
results showed that the inhibitor of Rap1, FTS (100 µM), significantly reduced the 
relaxation effect of G-1, further conformed the involvement of Epac/Rap1 in the GPER-
mediated coronary artery relaxation. In vitro studies have evidenced several underlining 
mechanisms for Epac/Rap1induced vascular relaxation, including attenuation of RhoA 
activity (241) and indirect modulation of K
+
 channel activity (183, 190). 
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Increase in RhoA activity stimulated by various vasoconstrictors leads to 
phosphorylation of MYPT1, at Thr
853
, not at Thr
696
, via Rho kinase (49, 109). The 
elevated phosphorylation of MYPT1 largely inhibits MLCP activity, therefore, 
sustaining the vascular smooth muscle contraction by keeping MLC phosphorylation 
from falling. On the other hand, when MYPT1 is dephosphorylated, MLCP will be 
activated to dephosphorylate MLC and induce relaxation (106). Evidences from other 
people’s work and ours have shown that cAMP/PKA signaling may inhibit RhoA by 
phosphorylating RhoA at Ser
188
, thereby releasing the inhibition of RhoA/Rho kinase on 
MLCP, thus allowing MLCP dephosphorylate MLC and cause relaxation of vascular 
smooth muscle independent of intracellular Ca
2+
 level (74, 182, 234). Since the 
phosphorylation of MYPT-1 at Thr-
696
 site is often spontaneously phosphorylated under 
resting conditions and is insensitive to stimuli by most agonists (106, 109), we only 
studied the phosphorylation of Thr
853
 of MYPT-1. Our results showed that: the 
antagonist of Epac, ESI-09, significantly inhibited G-1-induced phosphorylation of 
RhoA at Ser
188
 and restored G-1-reduced RhoA activity; Epac agonist, 007, on the other 
hand, increased phosphorylation of RhoA and decreased RhoA, similar to that of G-1 
and PKA agonist, 6-Benz-cAMP; At the phosphorylation of Thr
853
 of MYPT1, when 
either PKA and Epac antagonist present, the decrease of the p-MYPT-1 mediated by G-1 
was partially restored, when both present, they exerted adding effect and completely 
restored the p-MYPT-1. Together these findings demonstrate that Epac plays a similar 
role as PKA in GPER-mediated coronary relaxation via inhibition of RhoA and p-
MYPT-1.  Consisting with our findings are findings from rat aortic smooth muscle, gut 
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and airway smooth muscles, in which, Epac agonist 007 as well as the vasodilator PGI2 
analog, cicaprost, increased Rap1 activity and decreased RhoA activity (241). Activation 
of a plasma membrane-bound G protein-coupled receptor TGR5, known as GPBAR1 (G 
protein-coupled bile acid receptor1), has also been reported causing relaxation of gastric 
smooth muscle, which is mediated through inhibition of RhoA/Rho kinase pathway via 
cAMP/Epac-dependent stimulation of Rap1 (185). 
The roles that Epac plays in respect to PKA in mediating cAMP signaling can be 
separate, opposing, or additive and synergetic, depending on the tissue or cell types and 
their various conditions. In renal, PKA and EPAC play separate roles and are engaged in 
very different downstream physiological functions in principal cells and stellate cells 
(51). In large number of cell types, PKA mediates pro-apoptotic response to cAMP; 
while Epac mediates the anti-apoptotic response (97). Similarly, in neurons, Epac and 
PKA play opposing roles in regulating axon guidance (152). In heart, PKA and Epac 
function cooperatively in neo-formation of gap-junction of rat cardiac myocytes (203); 
additionally, in an additive and independent manner, Epac and PKA phosphorylates 
phospholamban and ryanodine receptor in the regulation of cardiac function (164). 
However, Epac and PKA exert opposing effects on Ca
2+
-activated force and 
myofilament Ca
2+
 sensitivity in those rat cardiac myocytes (30). In vascular SMCs, both 
PKA and Epac pathways are necessary for cell growth inhibition. Epac synergises with 
PKA to mediate cAMP-induced cell growth arrest (87). In cAMP-mediated vascular, gut 
and airway smooth muscle relaxation, Epac and PKA are involved independently in the 
downstream signaling (185, 241). In this study we showed that Epac and PKA exert 
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additive effect in mediating GPER downstream signaling at the phosphorylation of 
MYPT-1, although they signal in separate pathways as confirmed by the result that 
neither Epac agonist nor antagonist had any effect on the phosphorylation of VASP at 
Ser
157
, a marker for monitoring PKA activity (241).  
Ion channel recording study in rat aortic SMCs has shown that cAMP-mediated 
activation of Epac inhibited KATP channel activity via activation of Ca
2+
-sensitive protein 
phosphatase 2B (183). A more recent study suggests that Epac mediated rat mesenteric 
artery relaxation by limiting Ca
2+
 entry via voltage-sensitive Ca
2+
 channels via SMCs 
hyperpolarization caused by: 1) activation of BKCa channels by Ca
2+
 sparks released 
from ryanodine receptors, and 2) the activation of SKCa/IKCa channels of endothelial 
cells (190). Our previous work has shown that G-1 treatment of porcine coronary artery 
SMCs opens BKCa channels. The activation of these channels requires the integrity of 
cytosol signaling (236). We may speculate that either PKA or Epac or both may be 
involved in the BKCa channels opening mechanism of GPER.  
 
4.5 CONCLUSION 
In conclusion, the results of this study confirm that GPER-mediated porcine 
coronary relaxation involves both Epac and PKA signaling to inhibit the RhoA/ROCK 
effect on MLCP, therefore, causing decreased phosphorylation of MLC and relaxation of 
coronary artery (Fig. 22). These findings offer clearer understanding on the role of 
GPER in vascular tone regulation and provide a molecular basis for GPER as a potential 
drug target in preventing and treating cardiovascular disease in women.   
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Figure 22. Proposed mechanism of Epac and PKA pathways in GPER-mediated 
porcine coronary artery relaxation signaling. When GPER is activated by G-1, it 
activates Gs protein. Gs stimulates adenlylyl cyclase (AC) and increases cAMP 
generation. Cyclic AMP activates both downstream targets, Epac and PKA.  Epac 
activates Rap1, then RhoA is phosphorylated at serine 188 by both Rap1 signaling and 
PKA, thereby the activity RhoA and its effector Rho Kinase (ROCK) is inhibited, thus 
releasing the inhibition on MLCP by decreasing the phosphorylation of MYPT1, the 
myosin phosphatase target subunit 1 of MLCP, leading to decreased phosphorylation of 
MLC20 and coronary artery relaxation. 
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CHAPTER V 
ACTIVATION OF G PROTEIN-COUPLED ESTROGEN 
RECEPTOR 1 ENHANCES ENDOTHELIN-1-INDUCED 
CORONARY ARTERIES CONSTRICTION VIA 
TRANSACTIVATION OF EGFR 
 
5.1 INTRODUCTION 
Cardiovascular disease continues to claim the lives of more women in the U.S. 
than any other health problem, with coronary heart disease (CHD) as the single leading 
cause of mortality (66). Although lipid-lowering statins and antiplatelet aspirin reduce 
the risk of CHD in men, these therapies are ineffective for women (15, 175). There is an 
urgent need for developing a means of preventing CHD in women. In early menopause 
estrogen therapy helps protect against CHD (88, 161); yet paradoxically, estrogen is 
associated with an increased risk of both CHD and stroke in postmenopausal women> 65 
years of age (130). There is no means of effectively preventing or treating CHD in this 
population who are at highest risk for cardiovascular mortality and morbidity. 
A highly novel and promising therapeutic target for treating cardiovascular 
disease is the recently-identified membrane-associated, G-protein-coupled estrogen 
receptor 1 or GPER (78). GPER activation reduces blood pressure, heart and brain 
infarct extent after ischemia-reperfusion damage or stroke (45, 238), and relaxes 
peripheral blood vessels (75, 127). Moreover, we have recently demonstrated that 
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selective activation of GPER relaxes porcine coronary arteries and targets smooth 
muscle cells from human coronary arteries (236). On the other hand, GPER induces 
vasoconstriction in the kidney (114). Thus, GPER can mediate opposite effects on blood 
vessels, and we propose that it is very likely that these dual actions of GPER can 
contribute to the seemingly paradoxical effects of estrogen in regulating coronary artery 
function. However, the mechanism underlining the GPER-mediated vasoconstriction is 
far from completed.  
In human coronary microarteries, estrogen potentiated angiotensin II-induced 
vasoconstriction via GPER and EGFR (epidermal growth factor receptor) activation 
(12). Direct constriction effect of GPER activation was shown in an isolated rat kidney 
perfusion study, when the artery was under a pre-constriction stage, addition of GPER 
agonist G-1induced relaxation, however, under conditions without any vasoconstriction 
agent, G-1 alone caused artery contraction and the vasoconstriction may be blocked by 
inhibitors of EGFR and ERK1/2 (17, 114). Filardo et al. (56) also provided evidences on 
GPER transactivation of EGFR. They reported that in MCF-7, SKBR3 and MDA-MB-
231 cells, estrogen caused attenuation of ERK1/2 activity via Gβγ-dependent transaction 
of EGFR by activation of GPER. But, how GPER is mediating these opposing effects of 
estrogen and whether GPER contributes to the paradoxical effects of estrogen in 
postmenopausal women remain unknown. In this study, we provide answers to these 
important questions by testing the hypothesis that activation of GPER enhances coronary 
artery contraction by the EGFR/ERK1/2 signaling pathway. 
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5.2 MATERIALS AND METHODS 
5.2.1 Supply of coronary arteries 
Porcine hearts were obtained from local abattoirs, K&C meat processing and 
placed into ice-cold Krebs buffer of the following composition: 131.5 mM NaCl, 5 mM 
KCl, 1.2 mM NaH2PO4, 2.5 mM MgCl2, 1.2 mM CaCl2, 2 g glucose and 2 g NaHCO3 in 
1 L with pH 7.4 (The solution was previously oxygenated with 95% O2-5% CO2 for 30 
minutes). Hearts were kept on ice during transport to the laboratory. Coronary arteries 
were dissected from porcine hearts and the protocol was in compliance with the Texas 
A&M University Institutional Animal Use Protocol. 
5.2.2 Tension studies 
The left anterior descending coronary artery (LAD) were dissected and cleaned 
of excess collective tissue and fat tissue. To eliminate indirect effects of endothelium-
derived vasoactive factors, the endothelium were removed physically by rubbing the 
intimal surface and tested by observing the absence of bradykinin-induced relaxation of 
PGF2α induced contraction. LADs were cut into ~3 mm rings and mounted on two 
parallel tissue supports, with one support fixed to a stationary chamber and the other 
attached to a force transducer (AD instruments). Isometric contractile force was recorded 
on a computer using LabChart software. The tissue bathing solution was Krebs buffer, 
oxygenated continuously with 95% O2-5% CO2 and maintained at 37°C. Coronary artery 
rings were equilibrated for 90 min under an optimal resting tension of 20mN, and bath 
solution was changed every 30 min to prevent accumulation of metabolic products. After 
equilibration, vasoconstrictor prostaglandin (PG)F2α (1 μM) was administrated to check 
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rings contractility. Inhibitors were added 30 min prior to the measurement of a complete 
G-1 concentration-response relationship (1 to 3000 nM). Vasodilatory responses were 
calculated as the percent reduction in tension from the pre-contracted state.  
5.2.3 Cell cultures 
The method to be used to disperse cells has been described by Chamley-
Campbell et al.(32). Briefly, coronary arteries were dissected, cut into pieces and placed 
into 3mg/ml collagenase in modified dissociation medium (110 mM NaCl, 5 mM KCl, 2 
mM MgCl2, 0.16 mM CaCl2, 10 mM HEPES, 10 mM NaHCO3, 0.5 mM KH2PO4, 0.5 
mM NaH2PO4, 0.49 mM EDTA, 10 mM Taurine 10 mM glucose and 15% fetal bovine 
serum) at 37°C for 1 h, followed by 0.5mg/ml elastase for 1h in the same medium. Then 
the tissue pieces were dispersed into single cell with complete SmBM basal medium 
(Lonza) and seeded into 60-mm gelatin-coated plastic dishes with density of 
2x10
5
cells/ml. Primary cultured porcine coronary artery smooth muscle cells (SMCs) 
and human coronary artery SMCs (Cascade Biologics) were maintained in complete 
SmBM basal medium.  Cell cultures were kept at 37°C and under 5% CO2 in a 
humidified incubator. The purity of porcine coronary artery SMCs was verified by 
positive staining with smooth muscle-specific α-actin (120). Coronary artery SMCs were 
cultured to 80% -90% confluence, and then we employed passage 3-4 for porcine 
coronary artery SMCs or passage 5-6 for human coronary artery SMCs. 
5.2.4 Western blots 
After pretreated with inhibitors and followed by different treatments in isometric 
tension studies, LAD coronary artery rings were snap-frozen in liquid nitrogen, 
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pulverized and then lysed in RIPA lysis buffer (Sigma) with protease and phosphatase 
inhibitors. Porcine and human coronary artery SMCs were harvested and lysed in the 
same solution. Protein concentrations were determined by Pierce BCA protein assay and 
samples were separated on precast 4%-12% Bis-Tris gels (Invitrogen) according to the 
manufacturer’s instructions. Then proteins were transferred to PVDF membrane (EMD 
Millipore) at 100 V for 2 h. Membranes were blocked with 5% nonfat milk for 1 h at 
room temperature and then incubated with first primary antibody in TBST containing 
5%nonfat milk protein for overnight at 4°C. After washing and incubating with second 
antibody, the membranes were ready for chemifluorescent detection. Membranes were 
stripped and immunoblotted with β-actin antibody for protein loading control. 
5.2.5 Statistics 
Vascular function studies were analyzed by different treatments (the presence or 
the absence of inhibitors in G-1 accumulation concentration responses, or G-1 
pretreatment with the presence or absence of inhibitor in ET-1 accumulation 
concentration responses) using two-way analysis of variance (ANOVA) for multiply 
groups and Student’s t-tests between paired groups. One way ANOVA was used to 
detect significant differences among all groups of immunoblotting detection data and 
student’s t-testis used in paired groups. Data was expressed as means ± SE and analyzed 
with Prism program (GraphPad Software Inc., San Diego, CA). Bonferroni correction 
was used to correct type 1 error associated with multiple comparisons. A P value ≤0.05 
indicated a significant difference. 
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5.2.6 Materials 
Antibodies were purchased from Santa Cruz Biotechnology. Both G-1 and G36 
were purchased from Azano Pharmaceuticals Incorporation. The inhibitors tested in 
tension studies were purchased from Tocris Bioscience. 
 
5.3 RESULTS 
5.3.1 Coronary contraction and the functional role of Gβγ 
Although the activation of GPER causes stimulation of Gβγ signaling has been 
implicated in MCF-7, SKBR3 and MDA-MB-231 cells (56), there is no direct evidence 
that has shown Gβγ activation following stimulation of GPER in coronary arteries. We 
tested whether GPER enhances coronary contraction by applying cumulative ET-1 
concentration-response relation in the presence or absence of G-1 or G-1 + G36in 
porcine left anterior descending coronary arteries.  As shown in Fig.23A, arteries pre-
incubated with G-1 (1 μM ) showed an enhancement of ET-1 concentration response, a 
significant higher contraction force was induced compared after ET-1 concentration 
reached to 10 nM, compared to the control group, that is the identical concentration 
ofET-1 alone group, and GPER antagonist,G36 (10 μM), blocked this constriction 
enhance effect of G-1. The maximal contraction of G-1 pretreated artery rings were 
65.59 ± 5.41 mN/mg without changing EC50 (Table 5). Next, we tested the functional 
role of Gβγ in GPER-mediated coronary artery contraction. The specific Gβγ inhibitor 
Gallein was used to block Gβγ cell signaling in these artery rings. Gallein (10 μM) 
markedly increased G-1-induced relaxation with maximal relaxation of 65.39 ± 2.25 % 
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and no change on EC50 (Fig.23B, Table 6). These findings from tension studies suggest 
that Gβγ is involved in GPER-mediated coronary contraction. 
 
 
 
 
Figure 23. G-1 promotes ET-1-induced coronary arteries contraction and Gβγ is 
involved in G-1-enhancedvasoconstriction. A: concentration-response relationship for 
ET-1-induced contraction in the presence or absence of G-1 or G-1 + G36. Each point 
represents the mean contractile force± SE. Contractile force was the force generated by 
artery rings calibrated with artery weight with unit mN/mg. **P < 0.01 compared with 
ET-1 group using two-way ANOVA. B: concentration-response relationship for G-1-
induced porcine coronary artery relaxation in the presence or absence of selective Gβγ 
inhibitor Gallein. Each point represents the mean relaxation effect ± SE.*P < 0.05, 
compared with G-1 group. 
 
 
 
 
 
Table 5. Effects of compounds on porcine coronary artery contraction response to 0.3 
μM ET-1. Values are given as mean contractile force ± SE. The number of experiments 
is indicated in parentheses. Artery rings were pretreated with each of the inhibitors and 
the results were compared to ET-1 alone group (
+
ET-1). ***P<0.001, significant 
difference compared with ET-1 alone group (
+
ET-1) by using two-way ANOVA. 
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Table 6. Effects of Gβγ/EGFR/ERK1/2 signaling compounds on porcine coronary 
artery relaxation response to 3 μM G-1. Values are given as mean relaxation effect ± 
SE. The number of experiments is indicated in parentheses. Artery rings were pretreated 
with each of the inhibitors and the results were compared to G-1 alone group (
+
G-
1).**P<0.01, ***P<0.001, significant difference compared with G-1 alone group (
+
G-
1)by using two-way ANOVA. 
 
5.3.2 EGFR transactivation in coronary contraction 
Activation of EGFR has been implicated in many cardiovascular diseases (133), 
and may provide new targets for control of vascular smooth muscle cell proliferation in 
response to arteries injury (100). Although evidence has shown that GPER induces 
EGFR transactivation in breast cancer cells (55), there is no information available in 
vascular smooth muscle. We first tested the functional role of EGFR in tension study by 
employing AG1478, a selective EGFR tyrosine kinase inhibitor (98).  AG1478 (5 μM) 
enhanced G-1-induced relaxation by more than 50% (Fig.24A, Table 6), reaching 
statistical significance at 30 nM through 3 μM, but there was no change in EC50 value, 
suggesting that EGFR is involved in GPER-mediated vascular tone regulation. Further, 
we tested G-1 effect on EGFR transactivation in porcine coronary artery SMCs by  
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detecting tyrosine phosphorylation of EGFR with Western blot.  G-1 (1 μM) clearly 
increased EGFR phosphorylation at both 5 and 10 min., similar to EGF (10 ng/ml), 
while AG1478 attenuated the effect of G-1 on phosphorylation of EGFR (Fig. 24B). 
Src is the upstream of EGFR transactivation mediated by GPER in breast cancer 
cells (55). Evidence has shown that Src is involved in modulation of coronary artery 
contractility (154). Thus, we determined whether Src is involved in GPER mediated 
potentiation of coronary artery contraction by pretreating coronary artery rings with 
inhibitor of Src, phosphoprotein phosphatase 2 (PP2), and measuring the cumulative ET-
1 concentration response. As expect, G-1 pretreatment enhanced ET-1 induced coronary 
artery comparing to ET-1 group, while Src inhibitor PP2 (10 μM) blocked the enhanced 
contraction effect of G-1. The maximal contraction in the presence of both PP2 and G-1 
was 28.30 ± 4.21 mN/mg without changing EC50 (Fig.24C and table 5). Taken together 
with vascular functional studies and Western blot analysis, these findings suggest that 
GPER activation potentiates coronary artery contraction through transactivation of 
EGFR via Src. 
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Figure 24. EGFR transactivation is involved in the coronary tone regulation of G-1. 
A: Concentration-response relationship for G-1-induced porcine coronary artery 
relaxation in the presence or absence of selective GPER inhibitor AG1478. Each point 
represents the mean relaxation effect ± SE.*P < 0.05, ***P<0.001, compared with G-1 
group using two-way ANOVA.B: Western blot detection of phosphorylation of EGFR in 
porcine coronary artery SMCs. Cells were incubated with DMSO (solvent control), EGF 
(100ng/ml) 10min, G-1 (1μM) 2min, G-1 (1 μM) 5min, G-1 (1 μM)10min and AG1478 
(5 μM) +G-1(1 μM). Top: a representative Western blot from 3 individual 
experiments. Bottom: bar graph of the quantitative data of the Western blot bands 
evaluated by densitometry. Protein amounts were normalized to β-actin, which was 
employed as a control for protein loading.*P < 0.05, compared to the group as indicated 
in the graph. C: concentration-response relationship for ET-1-induced contraction in the 
presence or absence of G-1 or G-1 + PP2. Each point represents the mean contractile 
force ± SE. Contractile force was the force generated by artery rings calibrated with 
artery weight with unit mN/mg. **P < 0.01, ***P < 0.001,compared with ET-1 group 
using two-way ANOVA. 
 
5.3.3 ERK1/2 activation in coronary contraction 
GPER activation can stimulate Src-related tyrosine kinase activity-dependent 
EGFR transactivation and then cause ERK1/2 phosphorylation in breast cancer cells 
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(55). Inhibition of ERK1/2 with PD98059 significantly attenuated G-1-induced 
vasoconstriction of rat renal arteries (114). We tested the role of ERK1/2 by applying 
ERK1/2 upstream MEK inhibitor PD98059 in tension study and detecting phospho-
ERK1/2 in immunoblotting. In the presence of both PD98059 (1μM), G-1-induced 
relaxation of coronary arteries was significantly increased with maximal relaxation of 
66.86 ± 3.12% (Fig. 25A, Table 6). In western blots, we tested G-1 effect on ERK1/2 
activity in porcine coronary artery SMCs by detecting phosphorylation of ERK1/2 in the 
presence or absence of adenlyly cyclase inhibitor SQ22536.  In the presence of SQ 
22536 (100 μM), G-1 (1 μM) significantly increased ERK1/2 phosphorylation at all time 
points with the highest at 30 minutes similar to EGF (10 ng/ml). On the other side, in the 
absence of SQ22536, G-1 (1 μM) decreased about one and half of phospho-ERK1/2at 
all-time points. As expect, G36blocked G-1 stimulation effect in the presence of 
SQ22536 as well as the inhibition effect of G-1 in absence of SQ22536 (Fig. 25B and 
C). Together, these findings suggest that GPER may promote coronary artery contraction 
via ERK1/2 activation. 
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Figure 25. G-1 activates ERK1/2 activity in porcine coronary arteries and porcine 
coronary artery SMCs in the presence of SQ 22536. A: concentration-response 
relationship for G-1 in the presence or absence of PD98059, a selective inhibitor of 
MEK kinase. Results are expressed as means relaxation effect ± SE of 6 experiments. 
**P < 0.01, compared with the G-1 group by two way ANOVA analysis. B: A 
representative Western blot from 3 individual experiments of phospho-ERK1/2 detection 
in porcine coronary artery SMCs. Artery Cells were pretreated by in presence or absence 
of adenlyly cyclase inhibitor SQ22526, then incubated with DMSO (solvent control), G-
1 (1 μM, with different collecting time points), G36 (10 μM) + G-1 (1 μM), and EGF 
(10ng/ml), a positive control. Protein amounts were normalized to β-actin, which was 
employed as a control for protein loading. C: Bar graph of the quantitative data of the 
Western blot bands evaluated by densitometry. 
 
5.4 DISCUSSION 
Although accumulative evidence suggests that GPER plays an important role in 
mediating cardiovascular actions of estrogen, our understanding of the mechanisms 
underlying these actions is extremely limited and sometimes contradictory. For example, 
a vasodilatory effect of GPER activation has been demonstrated in rat carotid (24), rat 
aorta (127), human mammary arteries  (75), and porcine coronary arteries  (144, 236); 
On the contrary, it has also been reported that GPER mediates a vasoconstrictor effect in 
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isolated perfused rat kidneys, and this constriction was blocked by inhibitors of EGFR 
and ERK1/2 (114). The mechanisms by which activation of GPER regulates coronary 
artery relaxation have been extensively investigated in chapter III and chapter IV. 
However, knowledge of GPER potentiation of coronary artery contraction in the 
cardiovascular system is lacking. This study demonstrated that activation of GPER 
induces EGFR transactivation and ERK1/2 activation via Gβγ signaling and thus 
promotes coronary artery contraction. 
GPER is involved in estrogen potentiated aldosterone-angiotensin II-induced 
vasoconstriction in human coronary microarteries (12). Kurt et al. (114) further reported 
that G-1 induced vasoconstriction in basal renal perfusion pressure in the isolated rat 
kidneys. In contrast, G-1 induced vasodilation when the perfusion pressure is elevated 
by phenylephrine. However, no studies show a vasoconstriction effect of GPER on 
coronary arteries, which could contribute to estrogen-linked increased risk of heart 
attack in older women (130). We observed that G-1 (1 μM) enhanced the contraction 
effect of ET-1 in porcine coronary arteries, and G36 (10 μM), a selective GPER 
antagonist inhibited the action of G-1, suggesting that GPER activation mediates 
vasoconstriction as well as vasorelaxation.  
After binding of GPER-specific ligands, Gα subunit in the activated trimetric G 
protein dissociates from the Gβγ complex and activates adenylate cyclase, resulting in 
the production of cAMP. The remaining Gβγ protein complex also acts as a signaling 
effector by activating Src tyrosine kinase, which binds to an adaptor protein shc. This 
complex activates membrane associated matrix metalloproteinase (MMP) and 
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subsequent release of EGF (epidermal growth factor) into extracellular space (177). EGF 
activates the EGFR (EGF receptor) through autocrine or paracrine to induce the 
activation of ERK1/2(57). Filardo et al. demonstrated that Gβγ protein complex 
mediated GPER downstream signaling in MCF-7 cells, SKBR3 cells and MDA-MB-231 
cells (55).  Our result that the selective Gβγ signaling inhibitor Gallein significantly 
increased G-1 induced coronary relaxation directly revealed the role of Gβγ in mediating 
coronary contraction effect of GPER activation. 
EGFR transactivation plays an important role in vascular smooth muscle function 
and is likely involved in many cardiovascular diseases(100). Activation of EGFR has 
been implicated in blood pressure regulation, endothelial dysfunction, neointimal 
hyperplasia, atherogenesis, and cardiac remodeling (133). EGFR is involved in the 
mechanism of pressure-induced myogenic tone in mouse mesenteric resistance arteries 
(131). GPER-mediated renal artery constriction was inhibited by EGFR inhibitor, 
indicating involvement of EGFR in GPER-mediated regulation of vascular tone (114). 
However, no study has been found on how the modulation of GPER on EGFR signaling 
impacts coronary artery tone. Our results showed the functional role of EGFR in GPER-
mediated potentiation of coronary artery constriction. The EGFR inhibitor AG1478 
inhibited the contractile effect of GPER by increasing G-1 induced coronary artery 
relaxation. In Western blots, G-1 treatment increased the phosphorylation of EGFR in 
porcine coronary artery SMCs. Furthermore, in breast cancer cells, Src is upstream of 
EGFR transactivation mediated by GPER (55). Src is involved in rat thoracic aorta 
contraction mediated by α1-adrenoceptors and in pressure-induced myogenic tone of 
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mouse mesenteric resistance arteries via transactivation of EGFR (131, 218). We 
employed PP2, the selective inhibitor of Src-family tyrosine kinases, to disrupt Src 
tyrosine kinase induced signaling and measured a cumulative ET-1 concentration-
response relation in the presence or absence of G-1. PP2 reversed the enhanced 
contraction effect promoted by G-1, suggesting the functional role of Src. These 
experiments provided evidence for involvement of EGFR transactivation in the GPER 
potentiated coronary artery contraction. 
The downstream of EGFR is the phosphorylation of ERK1/2, which has been 
implicated in vascular contraction by agonists of GPCR (G protein coupled receptors), 
such as ET-1 and growth factors (194). EGFR transactivation contributes to ET-1 
induced vasoconstriction in rabbit basilar arteries via the ERK1/2 signaling pathway 
(102). Activation of ERK1/2 increased vasoconstriction in hemorrhagic shock rats, 
while, selective inhibitor of both MEK1 and MEK2 U0126 inhibited vascular 
contraction (232), which is in consistent with our finding that MEK inhibitor PD 98059 
attenuate G-1 induce coronary artery contraction, leading to more relaxation. Filardo et 
al. (56) demonstrated that estrogen decreased ERK1/2 activity via Gβγ-dependent 
transaction of EGFR and it was through GPER-mediated cAMP-dependent signaling in 
breast cancer cells, suggesting the inhibitory effect of cAMP on ERK1/2 activity. We 
observed that GPER activation stimulated the phosphorylation of ERK1/2 via inhibition 
of adenylate cyclase by adenylate cyclase inhibitor SQ 22536, while in the absence of 
SQ22536 GPER attenuated phosphorylation of ERK1/2, indicating that cAMP maybe 
function as a switch between vasorelaxation and vasoconstriction mediated by GPER.  
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In conclusion, we have shown that GPER potentiated porcine coronary 
contraction which involves transaction of EGFR and the phosphorylation of ERK1/2 via 
Gβγ signaling (Fig. 26). This may help unravel the mystery of how estrogen can both 
prevent and contribute to coronary heart diseases. 
 
 
 
 
Figure 26. Proposed mechanism of GPER-enhanced porcine coronary artery 
contraction. When GPER is activated by agonist G-1, it activates the G protein Gβγ, 
which in turn stimulates tyrosine kinase Src, and then Src activates metalloproteinases 
which cleaves and releases the EGFR ligand precursors ProHB-EGF and causes 
transactivation of EGFR. Active EGFR stimulates its downstream target ERK1/2 and 
thus causes contraction. 
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CHAPTER VI 
SUMMARY 
 
6.1 CLINICAL IMPLICATIONS AND CONCLUSIONS 
Coronary heart disease (CHD) is the #1 killer of women in the U.S., claiming the 
lives of over 500,000 women each year. Estrogen protects women from CHD, but 
estrogen levels decline after menopause and postmenopausal women are at particularly 
high risk for CHD. More recently, evidence showed the beneficial effects of 
postmenopausal estrogen therapy in younger postmenopausal women but more harmful 
effect to older postmenopausal women by increase the risk of heart attack and strokes. 
The hypothesis that activation of GPER induces opposing responses in porcine coronary 
artery function (a more human-like model of heart function) has been extensively 
investigated in this dissertation. 
My work suggests that stimulation of GPER regulates porcine coronary artery 
tone by relaxing or contracting coronary arteries (Fig. 27). These dual effects of GPER 
may now help explain the paradoxical actions of estrogen on the cardiovascular system. 
My novel findings are that GPER activation: 1) relaxes coronary arteries via activation 
of Gs protein and its downstream target PKA and Epac; 2) through activation of MLCP 
via inhibition of RhoA activity by cAMP dependent stimulation of PKA in parallel with 
Epac; and 3) induces coronary contraction by transactivation of EGFR and its 
downstream signaling. These two opposing signaling mechanisms provide fine tuning of 
coronary artery tone under healthy conditions.  
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Figure 27. Proposed mechanisms of GPER dual actions on porcine coronary artery 
signaling. When GPER is activated by agonist G-1, it initiates both Gα/cAMP and 
Gβγ/EGFR signalings, and causes both vasorelaxation and vasoconstriction, with overall 
domination of vasorelaxation effect. 
 
The mechanism by which activation of GPER induces coronary artery relaxation 
by a Gs/cAMP-dependent pathway or enhances contraction by a Gβγ/EGFR-dependent 
pathway is of clinical importance. It may provide some explanation regarding the 
controversial actions of how estrogen can both prevent and contribute to CHD, and 
thereby open significant opportunities for the development of new pharmacological 
strategies that would provide many health benefits of estrogen while limiting the 
potentially dangerous side effects. Further, if the therapeutic potential of estrogen could 
be understood and harnessed, novel therapeutic approaches could be developed that 
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would bring the quality health benefits of estrogen therapy to all people, without the 
endocrine side effects. 
 
6.2 FUTURE STUDY 
6.2.1 Relationship between Ca
2+
 modulation and BKCa channel activity 
We observed that selective GPER agonist G-1 stimulates BKCa channel activity 
in both porcine and human coronary artery smooth muscle cells. Interestingly, G-1 is 
ineffective at stimulating BKCa channels in isolated excised membrane patches. These 
findings indicate that other regulatory mechanisms are involved in the opening of BKCa 
channel mediated GPER-induced relaxation. In vascular smooth muscle, an increase of 
BKCa channel activity from an elevation of cytoplasmic Ca
2+
 concentration consequently 
hyperpolarize the cell membrane to stop Ca
2+
 entry through L-type Ca
2+
 channels, 
decrease cytosolic Ca
2+
and thus relaxes smooth muscle (213), suggesting a negative 
feedback between Ca
2+
 mobilization and BKCa channel activities. Further, activation of 
Epac induces a potent activation of BKCa channels in cerebellar granule cells via 
Rap/p38 MAPK/ Ca
2+
 mobilization (209). Therefore, to determine the relationship 
between Ca
2+
 mobilization and BKCa channel activities could be a future research 
direction.  
 
6.2.2 Signaling related to AKAP 
The study described in chapter III demonstrated that the inhibitor of AKAP (A-
kinase anchor protein) -PKA interaction, FMP-API-1 (37), significantly inhibited G-1-
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induced coronary relaxation and block the inhibitory effect of G-1 on the 
phosphorylation of MYPT-1 (the myosin light chain phosphate regulatory subunit),  
suggesting that the binding of PKA to AKAP is required for GPER mediated coronary 
vasorelaxation. Broselid et al. (23) showed that the C terminal of GPER interacted with 
membrane-associated guanylate kinases (MAGUKs) and AKAP5 (186), one of the 
AKAPS reportedly expressed in vascular smooth muscle cells, in plasma membrane. 
AKAP5 regulated cAMP signaling by taking PKA close to GPER through the coupling 
of AKAP5 and MAGUKS. These observations indicate that the plasma complex formed 
by GPER, MAGUKs and AKAP may function as an entity, and disruption in any part of 
the interaction may alter the downstream signaling. Therefore, the function role of this 
plasma complex needs to be investigated in future studies. 
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